May 24, 2020

TECHNION – RUTH & BRUCE RAPPAPORT FACULTY OF MEDICINE

RESUME

1. PERSONAL DETAILS

Tsila Rosenvald-Zuckerman, MD

Date and place of birth: July 16, 1957; Tel Aviv, Israel

Marital status: Married + 2

2. ACADEMIC DEGREES

1987 MD (cum laude), Rappaport Faculty of Medicine, Technion – Israel Institute of

Technology, Haifa, Israel

1981 BSc, Faculty of Life Science, Tel Aviv University, Tel Aviv, Israel

3. ACADEMIC APPOINTMENTS

2017 - present Clinical Associate Professor, Rappaport Faculty of Medicine, Technion – Israel

Institute of Technology, Haifa, Israel

2012 - 2016 Clinical Assistant Professor, Rappaport Faculty of Medicine, Technion – Israel

Institute of Technology, Haifa, Israel

2008 – 2011 Clinical Lecturer, Rappaport Faculty of Medicine, Technion – Israel Institute of

Technology, Haifa, Israel

4. PROFESSIONAL EXPERIENCE

2019 to present Director, Department of Hematology and Bone Marrow Transplantation,

Rambam Health Care Campus, Haifa, Israel

2015 to present Member, Clinical Research Institute (CRIR), Rambam Health Care Campus,

Haifa, Israel

2006 to present Head, Bone Marrow Transplantation Unit, Rambam Health Care Campus, Haifa,

Israel

1997 to present Senior Physician, Division of Hematology, Rambam Health Care Campus,

Haifa, Israel

2

1997 Specialist Qualification Examination in Hematology, Stage I & 2

1992 – 1997 Permanent Senior Staff Member, Department of Internal Medicine A, Carmel

Medical Center, Haifa, Israel

1996 Fellowship, Bone Marrow Transplant Unit, Division of Hematology, USC

Medical School, California, USA

1994 – 1996 Residency Fellowship, Division of Hematology, USC Medical School,

California, USA

1993 Stage 3 FLEX Specialist Qualification Examination in Internal Medicine, Israel

1991 – 1992 Senior Physician, Department of Internal Medicine A, Carmel Medical Center,

Haifa, Israel

1991 Stage I FLEX Specialist Qualification Examination in Internal Medicine, Israel

1991 Residency rotation, Institute of Endocrinology, Carmel Medical Center, Haifa,

Israel

1990 – 1991 Residency rotation, Institute of Hematology, Carmel Medical Center, Haifa,

Israel

1990 Residency, Department of Internal Medicine A, Carmel Medical Center,

Haifa, Israel

1988 – 1990 Residency, Department of Internal Medicine A, Bnai Zion Medical Center,

Haifa, Israel

1987 – 1988 Internship, Bnai Zion Medical Center, Haifa, Israel

1987 ECFMG Examination

5. RESEARCH INTERESTS

1. Intra-patient genetic heterogeneity of acute myeloid leukemia using single cell analysis

and contribution of the micro-environment to the leukemic processes.

2. Infections in stem cell transplantation.

3. Complications of stem cell transplantation.

3

6. TEACHING EXPERIENCE

1988 – 1994 Lecturer, Introduction to Clinical Medicine course, 4th

-year medical students,

Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa,

Israel

1998 – 2014 Lecturer, Hematology courses, 4th

-year medical students, American TeAM

Program, Rappaport Faculty of Medicine, Technion – Israel Institute of

Technology, Haifa, Israel

1998 to present Lecturer, Hematology Physiology and Pathology course, 3rd

-year medical

students, lectures, Rappaport Faculty of Medicine, Technion – Israel Institute of

Technology, Haifa, Israel

1988 to present Lecturer, Internal Medicine clerkship, 5th

- and 6th

-year medical students,

Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa,

Israel

1998 to present Instructor, extended teaching for hematology trainees: bedside and frontal

courses, Rappaport Faculty of Medicine, Technion – Israel Institute of

Technology, Haifa, Israel

1999 to present Coordinator and lecturer, Preclinical-Clinical Integrated Systems (Hemato-

Oncology) course, 4th

-year medical students, Rappaport Faculty of Medicine,

Technion – Israel Institute of Technology, Haifa, Israel

2005 to present Instructor, Advanced Oncology course, educational lectures to nurses, Rappaport

Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

2005 – 2010 Instructor, Preparation course for licensing new immigrant physicians, Rappaport

Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

2010 to present Instructor, educational lectures on AML pathogenesis and treatment update,

hematology fellows, Rappaport Faculty of Medicine, Technion – Israel Institute of

Technology, Haifa, Israel

7. TECHNION ACTIVITIES

4

8. FACULTY ACTIVITIES

2010 to present Examiner of medical school candidates, Rappaport Faculty of Medicine, Technion

– Israel Institute of Technology, Haifa, Israel

2016 to present Instructor, Capsule course for clinical-year students, Rappaport Faculty of

Medicine, Technion – Israel Institute of Technology, Haifa, Israel

2019 to present Consultant to clinical-year students, Rappaport Faculty of Medicine, Technion –

Israel Institute of Technology, Haifa, Israel

9. PUBLIC PROFESSIONAL ACTIVITIES

2016 to present Chairperson, Committee for Regulation of Transplant Unit Recognition Criteria,

Israel Ministry of Health

2014 to present Member, Committee on Updates in Hemato-Oncology, Israel Cancer

Association

2010 to present Member, Israel Ministry of Health Appeals Committee for Health Services

outside Israel

2010 to present Grants reviewer, Israel Cancer Association, Israel Scientific Foundation (ISF),

Israel Cancer Research Fund (ICRF), Dotan Research Center

2005 to present Secretary, Israel Association for Bone Marrow Transplantation

Reviewer of Grant Applications

Israel Cancer Association

Regular Reviewer for Journals:

2014 to present European Journal of Haematology

2012 to present Blood Reviews Journal

2011 to present Blood Journal

2018 to present Leukemia

2018 to present Haematologica

10. MEMBERSHIP IN PROFESSIONAL SOCIETIES

INTERNATIONAL

5

Acute Leukemia Working Party within the European Society for Blood and Marrow

Transplantation

American Society of Hematology

European Society for Blood and Marrow Transplantation

NATIONAL

Israel Medical Association

Israel Society of Hematology and Blood Transfusion

Israel Working Party for Bone Marrow Transplantation (Research Secretary)

11. AWARDS AND HONORS

1994, 2000 Outstanding Lecturer, Rappaport Faculty of Medicine, Technion – Israel Institute

of Technology, Haifa, Israel

12. GRADUATE STUDENTS

Completed MD Theses

2004 Shani Ben-Harush. CA125 as a marker for the development of VOD. Primary supervisor:

T Zuckerman.

2005 Oren Caspi. Capillary leak syndrome in patients undergoing BMT Primary supervisor: T

Zuckerman.

2006 Orian Henig. The IL2R levels in patients with VOD. Primary supervisor: T Zuckerman.

2009 Sivan Benyamin. WT1 as an MRD marker for AML. Primary supervisor: T Zuckerman.

2016 Orly Rak. Lung complication in transplant patients. Primary supervisor: T Zuckerman.

Completed Basic Science Theses

2001 Luiza Akria. Detection of minimal residual disease in hematopoietic

autografts from lymphoma patients by PCR of lymphoma specific CDRIII sequences.

Primary supervisor: T Zuckerman.

2006 Ielena Mishenko. Low-grade lymphoma associated with HCV infection – evaluation of

pathogenetic mechanism. Primary supervisor: T Zuckerman.

2018 Dr. Orly Zohar. Infection with clostridium difficile in hematological patients. Primary

supervisor: T Zuckerman

6

2018 Dr. Mamduch Daraushe. The effect of ethnic origine on GVHD and overall outcome of

allogeneic stem cell transplantation in Israel. Primary supervisor: T Zuckerman

Completed MSc Theses

2013 Neta Pery. Identification and characterization of leukemic sub-population which are rarely

dividing. Primary supervisor: T Zuckerman; Co-supervisor: JM Rowe.

2017 Shira Atias. Interaction of leukemic cells with the microenvironment. Primary supervisor: T

Zuckerman.

Completed PhD Theses

MD Theses in Progress

Basic Science Theses in Progress

MSc Theses in Progress

PhD Theses in Progress

2013 Tal Shahar. Single cell analysis in patients with AML – genomic instability as potential

cause of relapse. Primary supervisor: T Zuckerman.

2018 Rawan Sabbah. The characterization of niche sub-populations in the bone marrow of acute

myeloid leukemia patients and their involvement in disease propagation and recurrence.

Primary supervisor: T Zuckerman

Supervision of Industrial Engineering & Management 4th

-Year Students

2016 Noga Bernenstein, Ayala Derei, Hadar Sharoni, Yotam Shimshovitz, Elia Safarb.

Improved utilization of resources in reducing the timeline between the diagnosis of

hematological malignancy and stem cell transplantation. Primary supervisor: T

Zuckerman. Co-supervisor: G Yom-Tov.

13. RESEARCH GRANTS

Competitive

1998 Israel Cancer Association (980047-B), Detection of minimal residual disease in

patients with B-cell non-Hodgkin’s lymphoma undergoing bone marrow

transplantation using the CDR3 immunoglobulin gene rearrangement. Division of

7

Hematology, USC School of Medicine, LA, and Rambam Health Care Campus,

Principal investigator: T Zuckerman.

1999 Rambam Medical Research Council, Capillary leak syndrome in patients

undergoing bone marrow transplantation. Principal investigator: T Zuckerman.

1999 State Public Committee for the Designation of Estate Funds (Grant 1890), BCL2

and immunoglobulin gene rearrangement in patients with hepatitis C virus

infection. Principal investigator: T Zuckerman.

2011 – 2013 Israel Cancer Association (20110054), 45,000 NIS per year, Analysis of single

leukemic stem cells at diagnosis and relapse Principal investigator: T Zuckerman.

2015 – 2017 Israel Cancer Association (20150081), 45,000 NIS per year, Heterogeneity of

acute myeloid leukemia at diagnosis and relapse as determined by single cell

genetic profile: implication on treatment and relapse mechanisms Principal

investigator: T Zuckerman.

2015 – 2017 Israel Cancer Research Fund, $30,000 per year, AML heterogeneity using single

leukemic cells; genomic analysis and clonal hierarchy. Principal investigator: T

Zuckerman.

2016 – 2018 Clinical Research Institute at Rambam (CRIR), 120,000 NIS per year. A single-

cell analysis approach for the investigation of intra-patient heterogeneity in acute

myeloid leukemia; implications on disease evolution and relapse Principal

investigator: T Zuckerman.

Industrial

1999 – 2002 Novartis (CSTI 571-113), 215,100 NIS, A study to determine the safety and

efficacy of STI571 in patients with chronic myeloid leukemia who are

hematologically or cytogenetically resistant or refractory to interferon-alpha or

intolerant of interferon. Co-investigator. Principal investigator: JM Rowe

1999 – 2002 Novartis (CSTI 571-114), 195,930 NIS, A study to determine the safety and

efficacy of STI571 in adult patients with chronic myeloid leukemia in accelerated

phase or Philadelphia chromosome positive acute lymphoblastic leukemia.

Co-investigator. Principal investigator: JM Rowe

2001 – 2002 Janssen-Cilag Ltd. (R115777), A phase II study evaluating the efficacy of the

fanesy transferase Inhibitor (FTI) R115777 in patients with refractory or relapsed

acute myeloid leukemia (AML). Co-investigator. Principal investigator: JM Rowe

2002 – 2004 Shire Pharmaceuticals (SPD 758-301), 15,516 NIS. A phase III randomized multi-

center study of troxacitabine alone, troxacitabine in combination with cytarabine

8

or high dose cytarabine alone in patients with acute myeloid leukemia in first

relapse. Co-investigator. Principal investigator: JM Rowe

2003 – 2006 Millennium Pharmaceuticals, Inc. (M34101-039; Velcade), 173,825 NIS, An

international multi-center randomized open label study of PS-341 versus high

dose dexamethasone in patients with relapse or refractory multiple myeloma.

Co-investigator. Principal investigator: JM Rowe

2003 – 2006 Millennium Pharmaceuticals, Inc. (M34101-040; Velcade), 78,707 NIS, An

international non- comparative open label study of PS-341 administered to

patients with multiple myeloma who experienced relapsed or progressive disease

after receiving at least four previous treatment regimens or experienced

progressive disease after receiving dexamethasone in Millennium Protocol

M34101-039. Co-investigator. Principal investigator: JM Rowe

2003 - 2009 PharmaNet Development Group (CC5013MM-010), 221,982 NIS. A multicenter

randomized parallel-group double blind placebo-controlled study of CC-5013 plus

dexamethasone versus dexamethasone alone in previously treated subjects with

multiple myeloma. Co-investigator. Principal investigator: JM Rowe

2005 – 2008 Johnson & Johnson (DOXIL-MMY-3001), 196,131 NIS, A randomized

controlled study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and

velcade (bortezomib) velcade monotherapy for the treatment of relapsed multiple

myeloma. Co-investigator. Principal investigator: JM Rowe

2004 – 2011 Johnson & Johnson (VISTA; MMY-3002), 185,489 NIS, An open label,

randomized study of velcade/melphalan/prednisone versus melphalan/prednisone

in subjects with previously untreated multiple myeloma. Co-investigator.

Principal investigator: JM Rowe

2003 - 2015 Fresenius Biotech (AP-AS-21-DE), 12,267 NIS. A randomized phase III

multicenter trial comparing a standard GVHD prophylaxis with cyclosporine A

and methotrexate with additional pretransplant ATG-Fresenius. Co-investigator.

Principal investigator: JM Rowe

2004 – 2007 Schering, 69,379 NIS, Reduction of Mab-Campath (Alemtuzumab) side effects

with subcutaneous administration and the addition of steroid. Co-investigator.

Principal investigator: JM Rowe

2008 – 2011 Hana Biosciences, Inc. (HBS407), A phase II study for the evaluation of the

safety and efficacy of weekly doses of Marqibo® (a liposome injection of

vincristine sulfate) in adult patients suffering from a second relapse of acute

9

lymphoblastic leukemia (ALL) with a Philadelphia chromosome negative or in

adult patients suffering from ALL with a Philadelphia chromosome negative after

two lines of failed chemotherapy treatments against leukemia. Co-investigator.

Principal investigator: JM Rowe

2008 – 2013 Paraxel (Gamida Cell Ltd.). A multi-center multi-national historical cohort

controlled study to evaluate efficacy and safety of transplantation of StemEx

umbilical cord blood stem cell expanded ex vivo, in subjects with hematologic

malignancies following myeloablative therapy. Co-investigator. Principal

investigator: JM Rowe

2010 - 2016 Enlivexpharm. 93,619 NIS, Phase 1/2a, multicenter, open-label study designed to

evaluate the safety, tolerability and preliminary efficacy of ApoCell

administration, a donor apoptotic cell-based product, for the prevention of

malignancies undergoing allogeneic sibling HLA-matched hematopoietic stem

cell transplantation. Principal investigator

2014 to present BST - PHASE1-01, 468,181 NIS. A phase I/IIa, open-label, uncontrolled study to

evaluate the safety and efficacy of Astarabine (BST-236) as single agent in

patients with refractory or relapsed Acute Myeloid Leukemia (AML) or Acute

Lymphoblastic Leukemia (ALL) disease. Principal investigator

2014 to present BIORAP, 20,000 NIS. Exploring the role of CCL1 chemokine and CCL1-Ig in

suppression of in vitro donor-recipient allo-reactivity. Principal investigator

2015 to present CELLECT, 14,400 NIS. The effect of pre transplantation apoptotic challenge with

FasL on engraftment and graft versus host disease (GVHD). Principal investigator

2016 - 2017 GILEAD. 208,403 ILS. A Phase 2b, Randomized, Double-Blind, Placebo-

Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics,

Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT)

Recipients with Respiratory Syncytial Virus (RSV) Infection of the Upper

Respiratory Tract Principal investigator

2016 to present CELLECT, 1,187,032 NIS. An Open-Label Phase I/II, Pilot, Staggered Four-

Cohort Safety and Proof-of-Concept Study of ApoGraft in the Prevention of

Acute Graft-versus-Host Disease (aGVHD). Principal investigator

2016 to present PLURISTEM. 227,623 NIS. A Phase I Open-label Dose-escalation Study to

Evaluate the Safety of Intramuscular Injections of PLX-R18 Cells in Subjects with

Incomplete Hematopoietic Recovery Following Hematopoietic Cell

Transplantation. Principal investigator

2016 to present JAZZ. 2,682,641 NIS. A Phase 3, Randomized, Adaptive Study Comparing the

10

Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of

Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing

Hematopoietic Stem Cell Transplant. Principal investigator

2016 to present Novartis. 307,500 NIS. A phase III randomized open-label multi-center study of

ruxolitinib versus best available therapy in patients with corticosteroid-refractory

acute graft-versus-host disease after allogeneic stem cell transplantation. Principal

investigator

2017 to present Novartis. 387,500 NIS. A phase III randomized open-label multi-center study of

Ruxolitinib vs. best available therapy in patients with corticosteroid-refractory

chronic graft vs host disease after allogenic stem cell transplantation (REACH 3).

Principal investigator

2017 to present INCYTE. 188,605$. A Randomized, Double-Blind, Placebo-Controlled Phase 3

Study of Itacitinib or Placebo in Combination with Corticosteroids for the

Treatment of First-Line Acute Graft-versus-Host Disease. Principal investigator

14. PUBLICATIONS

14.1 Thesis

1989 Cholinesterase and paraoxanase activity in population exposed to pesticides (cum laude)

14.2 Refereed Papers in Professional Journals

Basic Research

1. Richter ED, Rosenvald T, Caspi L, Levi S, Gruener N. Sequential cholinesterase tests and

symptoms for monitoring organophosphate absorption in field workers and in persons exposed

to pesticides spray drift. Toxicol-Lett. 1986.; 33(1-3):25-35;

2. Bitterman N, Lahat N, Rosenvald T, Kinarti A, Melamed Y, Bitterman H. Effect of hyperbaric

oxygen on tissue distribution of mononuclear cell subsets in the rat. J Appl. Physiol 1994; 77(5):

2355-2359.

3. Liebman HA, Rosenvald-Zuckerman T, Retzios A, Yasmin S, Kasper CK. Kinetics of factor

IX activity differ from that of factor IX antigen in patients with haemophilia B receiving high-

purity factor IX replacement. Haemophilia 1999; 5:174-180.

11

4. Zuckerman T, Zuckerman E, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe JM.

Bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Brit

J Haematol 2001; 1112:364-3649.

5. Zuckerman T, Zuckerman E, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe JM.

The effect of anti-viral therapy on t(14;18) translocation and immunoglobulin gene

rearrangement in patients with chronic hepatitis C virus infection. Blood 2001; 97:1555-1559.

6. Krivoy N, Hess I, Avivi I, Fineman R, Arbov L, Zuckerman T. Pharmacokinetic analysis of

once-daily gentamicin in immune-compromised adults with normal renal function. J Pharm

Technol 2002; 18:75-78.

7. Zuckerman E, Zuckerman T. Hepatitis C and B-cell lymphoma: the hemato-hepatologist

linkage. Blood Reviews 2002; 16:119-125.

8. Wolf DG, Lurain NS, Zuckerman T, Hoffman R, Satinger J, Honigman A, Saleh N, Robert ES,

Rowe JM, Kra-Or Z. Emergence of late cytomegalovirus central nervous system disease in

hematopoietic stem cell transplant recipients. Blood 2003; 101:463-465.

9. Shlush LI, Chapal-Ilani N, Adar R, Pery N, Maruvka Y, Spiro A, Shouval R, Rowe JM,

Tzukerman M, Bercovich D, Izraeli S, Marcucci G, Bloomfield CD, Zuckerman T, Skorecki

K, Shapiro E. Cell lineage analysis of acute leukemia relapse uncovers the role of replication-

rate heterogeneity and microsatellite instability. Blood 2012; 120(3):603-612.

10. Shouval R, Shlush LI, Yehudai-Resheff,S Ali S, Pery N, Shapiro E, Tzukerman M, Rowe JM,

Zuckerman T. Single cell analysis exposes intra-tumor heterogeneity and suggests that FLT3-

ITD is a late event in leukemogenesis. Exp Hematol. 2014; 42(6):457-463.

11. Yehudai-Resheff S, Attias-Turgeman S, Sabbah R, Gabay T, Musallam R, Fridman-Dror A,

Zuckerman T. Abnormal morphological and functional nature of bone marrow stromal cells

provides preferential support for survival of acute myeloid leukemia cells. Int J Cancer.

2019;144(9):2279-2289.

12. Brami I, Ini D, Sassonker N, Zaknoun M, Zuckerman T, Lewis EC. Immunosuppressive Drugs

Alter Alpha1-Antitrypsin Production in Hepatocytes: Implications for Epithelial Gap Repair.

Biol Blood Marrow Transplant 2020 Apr;26(4):625-633.

Clinical Research

1. Zuckerman E, Toubi E, Golan D, Rosenvald-Zuckerman T, Sabo E, Shmuel Z, Yeshurun D.

Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J

Cancer 1995; 72:447-451.

12

2. Zuckerman E, Rosenvald-Zuckerman T, Duer D, Levine A, Fong TL. Hepatitis C infection in

patients with non-Hodgkin B-cell lymphoma. Ann Int Med 1997; 127:423-428.

3. Zuckerman E, Zuckerman T, Douer D, Qian D, Levine A. Liver dysfunction in patients

infected with hepatitis C virus undergoing chemotherapy for hematological malignancies.

Cancer 1998; 83; 1224-1230.

4. Zuckerman E, Lanir A, Sabo E, Rosenvald-Zukerman T, Matter I, Yeshurun D, Eldar S.

Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J

Gastoenterol 1999; 94:1613-1618.

5. Levine MA, Nelson R, Zuckerman E, Zuckerman T, Govindrajan S, Valinluck B, Bernstein L.

Lack of association between hepatitis C infection and development of AIDS-related lymphoma.

J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:255-258.

6. Oren I, Zuckerman T, Avivi I, Finkelstein R, Yigla M, Rowe JM. Nosocomial outbreak of

Legionella pneumophila serogroup 3 pneumonia in a new bone marrow transplant unit:

evaluation, treatment and control. Bone Marrow Transplantation 2002; 30:175-179.

7. Oren I, Rowe JM, Sprecher H, Tamir A, Benyamini N, Akria L, Gorelik A, Dally N,

Zuckerman T, Haddad N, Fineman R, Dann EJ. A prospective randomized trial of

Itraconazole vs Fluconazole for the prevention of fungal infections in patients with acute

leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant

2006; 38(2):127-134.

8. Dann EJ, Bar-Shalom R, Tamir A, Haim N, Ben-Shachar M, Avivi I, Zuckerman T,

Kirschbaum M, Goor O, Libster D, Rowe JM, Epelbaum R. Risk-adapted BEACOPP

regimen can reduce the cumulative dose of chemotherapy for standard and high-risk

Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109(3):905-909.

9. Solomonov A, Zuckerman T, Goralnik L, Ben-Arieh Y, Rowe JM, Yigla M. Non-Hodgkin

lymphoma presenting as an endobronchial tumor: Report of eight cases and literature review.

Am J Hematol 2008; 83(5):416-419.

10. Avivi I, Avraham S, Koren-Miachelovitz M, Zuckerman T, Aviv A, Ofran Y, Benyamini N,

Nagler A, Rowe JM, Nagler RM. Oral integrity and salivary profile in myeloma patients

undergoing high-dose therapy followed by autologous SCT bone marrow transplant. Bone

Marrow Transplantation 2009; 43(10):801-806.

11. Brook O, Guralnik L, Hardak E, Oren I, Sprecher H, Zuckerman T, Engel A, Yigla M.

Radiological findings of early invasive pulmonary aspergillosis in immune-compromised

patients. Hematol Oncol. 2009; 27(2):102-106.

12. Solomonov A, Fruchter O, Zuckerman T, Brenner B, Yigla M. Pulmonary hemorrhage: a

novel mode of therapy. Respir Med. 2009; 103(8):1196-1200.

13

13. Blumenfeld Z, Zuckerman T. Repeated spontaneous pregnancies and successful deliveries

after repeated autologous stem cell transplantation and GnRH-agonist treatment. Oncologist

2010; 15(1):59-60.

14. Zuckerman T. Umbilical cord blood transplantation in adults: The ultimate solution for

patients without family matched donor? Hematology Update 2010; 2:17-19 (in Hebrew).

15. Zuckerman T, Benyamini N, Sprecher H, Fineman R, Finkelstein R, Rowe JM, Oren I.

SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience

with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant 2011;

46(9):1226-1230.

16. Zuckerman T, Katz T, Haddad N, Fineman R, Dann EJ, Avivi I, Ofran Y, Gavish I, Faibish T,

Sahar D, Hertz E, Sabo E, Reisner Y, Rowe JM. Allogeneic stem cell transplantation for

patients with chronic myeloid leukemia: Risk stratified approach with a long-term follow-up.

Am J Hematol. 2012; 87(9):875-879

17. Blumenfeld Z, Patel B, Leiba R, Zuckerman T. Gonadotropin-releasing hormone agonist may

minimize premature ovarian failure in young women undergoing autologous stem cell

transplantation. Fertil Steril. 2012; 98(5):1266-1270.

18. Krivoy N, Zuckerman T, Elkin H, Froymovich L, Rowe JM, Efrati E. Pharmacokinetic and

pharmacogenetic analysis of oral busulfan in stem cell transplantation: prediction of poor drug

metabolism to prevent drug toxicity. Curr Drug Saf. 2012; 7(3):211-217.

19. Bonstein L, Stemer G, Dann EJ, Zuckerman T, Fineman R, Haddad N. Alloimmune platelet

transfusion refractoriness circumvented by allogeneic stem cell transplantation. Transfusion.

Transfusion. 2013; 53(5):1019-1023.

20. Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, Mankuta D, Varda-

Bloom N, Rheingold L, Yeshurun M, Bielorai B, Toren A, Zuckerman T, Nagler A, Or R.

Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am

J Blood Res. 2013; 19;3(3):225-238.

21. Avivi I, Zuckerman T, Krivoy N, Efrati E. Genetic polymorphisms predicting methotrexate

blood levels and toxicity in adult non-Hodgkin's Lymphoma. Leuk Lymphoma. 2014;

55(3):565-570.

22. Oren I, Sprecher H, Finkelstein R, Hadad S, Neuberger A, Hussein K, Raz-Pasteur A, Lavi N,

Saad E, Henig I, Horowitz N, Avivi I, Benyamini N, Fineman R, Ofran Y, Haddad N, Rowe

JM, Zuckerman T. Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal

colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial. Am J

Infect Control. 2013; 41(12):1167-1172.

14

23. Mevorach D, Zuckerman T, Reiner I, Shimoni A, Samuel S, Nagler A, Rowe JM, Or R.

Single-infusion of donor mononuclear early apoptotic cells (ApoCell) as prophylaxis for graft-

versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation. A

phase I/IIa clinical trial. Biol Blood Marrow Transplant. 2014; 20(1):58-65.

24. Efrati E, Zuckerman T, Ben-Ami E, Krivoy N. MTHFR C677T/A1298C genotype: a possible

risk factor for liver sinusoidal obstruction syndrome. Bone Marrow Transplant 2014;

49(5):726-772.

25. Avivi I, Wittmann T, Henig I, Kra-Oz Z, Szwarcwort Cohen M, Zuckerman T, Horowitz NA,

Benyamini N. Development of multifocal leukoencephalopathy in patients undergoing

allogeneic stem cell transplantation-can preemptive detection of John Cunningham virus be

useful? Int J Infect Dis. 2014; 26:107-109.

26. Nevet MJ, Zuckerman T, Sahar D, Bergman R. Transformation of Sézary Syndrome into

CD30+ anaplastic large t-cell lymphoma after alemtuzumab therapy with evidence of

clonal unity. Am J Dermatopathol. 2015; 37(1):73-77.

27. Carmon L, Avivi I, Kovjazin R, Zuckerman T, Dray L, Gatt ME, Or R, Shapira MY. Phase

I/II

study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide

vaccine, in multiple myeloma patients. Br J Haematol. 2015; 169(1):44-56.

28. Wittmann T, Horowitz N, Benyamini N, Henig I, Zuckerman T, Rowe JM, Kra-Oz Z,

Szwarcwort Cohen M, Oren I, Avivi I. JC polyomavirus reactivation is common following

allogeneic stem cell transplantation and its preemptive detection may prevent lethal

complication. Bone Marrow Transplant. 2015; 50(7):984-991.

29. Andria N, Henig O, Kotler O, Domchenko A, Oren I, Zuckerman T, Ofran Y. Fraser D, Paul

M. Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria

among hematological cancer patients: a retrospective cohort study. J Antimicrob

Chemother. 2015; 70(11):3146-3153.

30. Ofran Y, Leiba R, Ganzel C, Saban R, Gatt M, Ram R, Arad A, Bulvik S, Hellmann I, Gino-

Moor S, Zuckerman T, Hoffman R, Horowitz N, Lavi N, Ringelstein S, Henig I, Hayun M,

Rowe JM. Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of

the "3 + 7" induction regimen for acute myeloid leukemia. Am J Hematol. 2015; 90(12):1159-

1164.

31. Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socie G, Eder M, Bonifazi F,

Bunjes D, Vigouroux S, Michallet M, Stelljes M, Zuckerman T, Finke J, Passweg J, Yakoub-

Agha I, Niederwieser D, Zucak G, Sengelov H, Polge E, Nagler A, Esteve J, Mohty M. Impact

of conditioning with total body irradiation in adult patients with T-cell acute lymphoblastic

15

leukemia who receive a myeloablative allogeneic stem cell transplantation: a report from the

acute leukemia working party of EBMT. Bone Marrow Transplant. 2016; 51(3):351-357.

32. Oren I, Hardak E, Zuckerman T, Geffen Y, Hoffman R, Yigla M, Avivi I. Does molecular

analysis increase the efficacy of bronchoalveolar lavage in the diagnosis and management of

respiratory infections in hemato-oncological patients? Int J Infect Dis. 2016 Jul 30; S1201-

9712(16)31118-1123.

33. Gorin NC, Labopin M, Czerw T, Pabst T, Blaise D, Dumas PY, Nemet D, Arcese W, Trisolini

S, Depei W, Huynh A, Zuckerman T, Meijer E, Cagirgan S, Cornelisen J, Houhou M, Polge

E, Mohty M, Nagler A. Autologous stem cell transplantation for adult acute myelocytic

leukemia in first remission: better outcome following busulfan and melphalan compared to

busulfan and Cyclophosphamide: a retrospective study from the Acute Leukemia Working

Party of the European society for Blood and Marrow Transplantation (EBMT).

Cancer. 2017 ;123(5):824-831

34. Benyamini N, Avivi I, Dann EJ, Zuckerman T, Lavi N, Katz T. Comparison of engraftment

following different stem cell mobilization modalities in patients with multiple myeloma treated

with a uniform induction regimen containing bortezomib, cyclophosphamide and

dexamethasone. Ann Hematol. 2017;96(3):461-467

35. Cohen YC, Zuckerman T, Yeshurun M, Perez G, Magen H, Henig I, Levi I, Shargian L,

Trestman S, Rouvio U, Naparstek E, Ganon-Elazar E, Avivi I, Ram R. Efficacy and Safety of

Autologous Hematopoietic Cell Transplantation in Elderly Patients with Multiple Myeloma: A

Retrospective National Multi-Site Cohort Study. Ann Hematol. 2017;96(2):271-278

36. Averbuch D, Tridello G, Hoek J, Mikulska M, Akan H, Yanez San Segundo L, Pabst T,

Özçelik T, Klyasova G, Donnini I, Wu D, Gülbas Z, Zuckerman T, Botelho de Sousa A,

Beguin Y, Xhaard A, Bachy E, Ljungman P, de la Camara R, Rascon J, Ruiz Camps I, Vitek A,

Patriarca F, Cudillo L, Vrhovac R, Shaw PJ, Wolfs T, O'Brien T, Avni B, Silling G, Al Sabty

F, Graphakos S, Sankelo M, Sengeloev H, Pillai S, Matthes S, Melanthiou F, Iacobelli S,

Styczynski J, Engelhard D, Cesaro S. Antimicrobial resistance in Gram-negative rods causing

bacteremia in hematopoietic stem cell transplant patients: intercontinental prospective study of

Infectious Diseases Working Party of the European Bone Marrow Transplantation group. Clin

Infect Dis. 2017;65(11):1819-1828 37. Paviglianiti A, Tozatto Maio K, Rocha V, Gehlkopf E, Milpied N, Esquirol A, Chevallier P,

Blaise D, Gac AC, Leblond V, Cahn JY, Abecasis M, Zuckerman T, Schouten H, Gurman G,

Rubio MT, Beguin Y, Corral LL, Nagler A, Snowden JA, Koc Y, Mordini N, Bonifazi F, Volt

F, Kenzey C, Robinson SP, Montoto S, Gluckman E, Ruggeri A. Outcomes of Advanced

Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT

16

Lymphoma and Cellular Therapy & Immunobiology Working Party Study. Biol Blood Marrow

Transplant. 2018 Nov;24(11):2265-2270. 38. Poiré X, Labopin M, Polge E, Blaise D, Chevallier P, Maertens J, Deconinck E, Forcade E,

Rambaldi A, Baerlocher GM, Zuckerman T, Volin L, Schouten HC, Ifrah N, Mohty M,

Esteve J, Nagler A. Hematopoietic stem cell transplantation for adult patients with isolated

NPM1 mutated acute myeloid leukemia in first remission. Am J Hematol. 2019;94(2):231-239 39. Raj K, Eikema DJ, McLornan DP, Olavarria E, Blok HJ, Bregante S, Ciceri F, Passweg J,

Ljungman P, Schaap N, Carlson K, Zuckerman T, de Wreede LC, Volin L, Koc Y, Diez-

Martin JL, Brossart P, Wolf D, Blaise D, Bartolomeo PD, Vitek A, Robin M, Yakoub-Agha I,

Chalandon Y, Kroger N. Family Mismatched Allogeneic Stem Cell Transplantation for

Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for

Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019; 25(3):522-528

40. Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, Chevallier P,

Cornelissen JJ, Reményi P, Maertens J, Poiré X, Craddock C, Socié G, Itälä-Remes M,

Schouten HC, Marchand T, Passweg J, Blaise D, Damaj G, Ozkurt ZN, Zuckerman T,

Cluzeau T, Labussière-Wallet H, Cammenga J, McLornan D, Chalandon Y, Kröger N.

Antilymphocyte globulin for matched sibling donor transplantation in patients with

myelofibrosis. Haematologica. 2019; 104(6):1230-1236

41. Beyar-Katz O, Lavi N, Ringelstein-Harlev S, Henig I, Yehudai-Ofir D, Haddad N, Fineman R,

Ofran Y, Nov Y, Sahar D, Moustafa-Hawash N, Rowe JM, Zuckerman T. Superior outcome

of patients with favorable-risk acute myeloid leukemia using consolidation with autologous

stem cell transplantation. Leuk Lymphoma. 2019;60(10):2449-2456

42. Hardak E, Fuchs E, Leskes H, Geffen Y, Zuckerman T, Oren I. Diagnostic role of polymerase

chain reaction in bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in

immunocompromised patients - A retrospective cohort study. Int J Infect Dis. 2019; 83:20-25

43. Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, Vural F,

Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Perez de

Oteyza J, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM,

Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer

EA, Sullivan KM; ZOE-HSCT Study Group Collaborators. Effect of Recombinant Zoster

Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A

Randomized Clinical Trial. JAMA. 2019;322(2):123-133.

44. Bitterman R, Hardak E, Raines M, Stern A, Zuckerman T, Ofran Y, Lavi N, Guralnik L, Frisch

A, Nudelman O, Paul M, Oren I. Baseline Chest Computed Tomography for Early Diagnosis of

Invasive Pulmonary Aspergillosis in Hemato-oncological Patients- a Prospective Cohort Study.

17

Clin Infect Dis. 2019;69(10):1805-1808

45. Ram R, Amit O, Zuckerman T, Gurion R, Raanani P, Bar-On Y, Avivi I, Wolach O.

Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a

multicenter historical prospective study. Ann Hematol. 2019;98(8):1927-1932

46. Stone A, Zukerman T, Flaishon L, Ben Yakar R, Rowe JM. Efficacy outcomes in the treatment

of older or medically unfit patients with acute myeloid leukaemia: A systematic review and

meta-analysis. Leuk Res. 2019, Jul;82:36-42

47. Shouval R, Labopin M, Gorin NC, Bomze D, Houhou M, Blaise D, Zuckerman T, Baerlocher

GM, Capria S, Forcade E, Huynh A, Saccardi R, Martino M, Schaap M, Wu D, Mohty M,

Nagler A. Individualized prediction of leukemia free survival following autologous stem cell

transplantation in acute myeloid leukemia. Cancer 2019, 125(20):3566-3573

48. Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, Vural F,

Pohlreich D, Zuckerman T, Issa NC, Gaidano G, Lee JJ, Abhyankar S, Solano C, Perez de

Oteyza J, Satlin MJ, Schwartz S, Campins M, Rocci A, Vallejo Llamas C, Lee DG, Tan SM,

Johnston AM, Grigg A, Boeckh MJ, Campora L, Lopez-Fauqued M, Heineman TC, Stadtmauer

EA, Sullivan KM; ZOE-HSCT Study Group Collaborators. Effect of Recombinant Zoster

Vaccine on Incidence of Herpes Zoster after Autologous Stem Cell Transplant: A Randomized

Clinical Trial. JAMA 2019, 322(2):123-133

49. Zuckerman T, Ram R, Akria L, Koren-Michowitz M, Hoffman R, Henig I, Lavi N, Ofran Y,

Horowitz NA, Nudelman O, Tavor S, Yeganeh S, Gengrinovitch S, Flaishon L, Tessler S, Ben

Yakar R, Rowe JM. BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit

for standard induction: a phase 1/2a study. Blood Adv. 2019;3(22):3740-3749.

50. Chemaly RF, Dadwal SS, Bergeron A, Ljungman P, Kim YJ, Cheng GS, Pipavath SN, Limaye

AP, Blanchard E, Winston DJ, Stiff PJ, Zuckerman T, Lachance S, Rahav G, Small CB,

Mullane KM, Patron RL, Lee DG, Hirsch HH, Waghmare A, McKevitt M, Jordan R, Guo Y,

German P, Porter DP, Gossage DL, Watkins TR, Marty FM, Chien JW, Boeckh M. A phase 2,

randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory

syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients. Clin

Infect Dis. 2019 Dec 3. [Epub ahead of print]

51. Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi N,

Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban R,

Tvito A, Rowe JM, Ganzel C. Bone marrow blast elimination by the fifth day of 7 + 3 induction

is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than

61 years of age: A long-term follow-up of a multi-center prospective study. Am J Hematol.

2020 Jan;95(1):E3-E5.

18

52. Rimar D, Butbul Aviel Y, Gefen A, Nevo N, Shen-Orr SS, Starosvetsky E, Rosner I,

Rozenbaum M, Kaly L, Boulman N, Slobodin G, Zuckerman T. Autologous Hematological

Stem Cell Transplantation for Systemic Sclerosis in Israel. Isr Med Assoc J. 2020

Feb;22(2):104-110.

53. Fuchs E, Hardak E, Oren I, Zuckerman T, Geffen Y. Clinical Spectrum, Diagnosis and

Outcome of Rare Fungal Infections in Patients with Hematological Malignancies: Experience of

15-Year Period from a Single Tertiary Medical Center. Mycopathologia. 2020, Apr;185(2):347-

355.

54. Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, Szer J, Wagner EM,

Zuckerman T, Mahuzier B, Xu J, Wilke C, Gandhi KK, Socié G; REACH2 Trial Group.

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med.

2020 May 7;382(19):1800-1810

55. Hernández-Boluda JC, Pereira A, Kröger N, Beelen D, Robin M, Bornhäuser M, Angelucci E,

Vitek A, Blau IW, Niittyvuopio R, Finke J, Cornelissen JJ, Passweg J, Dreger P, Petersen E,

Kanz L, Sanz J, Zuckerman T, Zinger N, Iacobelli S, Hayden P, Czerw T, McLornan D,

Yakoub-Agha I. Determinants of survival in myelofibrosis patients undergoing allogeneic

hematopoietic cell transplantation. Leukemia. 2020 Apr 14. [Epub ahead of print]

56. Shouval R, Labopin M, Bomze D, Baerlocher G, Capria S, Blaise D, Hänel M, Forcade E,

Huynh A, Saccardi R, Milone G, Zuckerman T, Remenyi P, Versluis J, Esteve J, Gorin N,

Mohty M, Nagler A. Risk stratification using FLT3 and NPM1 in acute myeloid leukemia

patients autografted in first complete remission" Bone Marrow Transplant, 2020, May 10. [Epub

ahead of print]

Case Reports

1. Hoffman R, Eliakim R, Zuckerman T, Rowe JM, Brenner B. Successful use of recombinant

activated factor VII in controlling upper gastrointestinal bleeding in a patient with relapsed

acute myeloid leukemia. J Thromb Haemost. 2003; 1(3):606-608.

2. Ofran Y, Avivi I, Gesundheit B, Or R, Rowe JM, Zuckerman T. Differentiation syndrome

with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome.

Am J Hematol. 2007; 82(4):332-333.

3. Blumenfeld Z, Benaroush M, Zuckerman T. Spontaneous pregnancy and normal delivery after

repeated autologous bone marrow transplantation and GnRH agonist treatment. Hum Reprod.

2007; 22(8):2346. Erratum in: Hum Reprod. 2007; 22(10):2799.

19

5. Beyar-Katz O, Kruzel Davila E, Zuckerman T, Fineman F, Haddad N, Okasha D, Henig I,

Leiba R, Rowe JM, Ofran Y. Nephrotic syndrome after hematopoietic stem cell transplantation:

a single center experience. Minerva Med. 2015; 106(6):355-357.

Review Papers

1. Zuckerman T, Rowe JM. Alternative donor transplantation in acute myeloid leukemia:

which source and when? Curr Opin Hematol. 2007; 14(2):152-161 (Invited).

2. Zuckerman T, Rowe JM. Hematopoietic stem cell transplantation for adults with acute

lymphoblastic leukemia. Curr Opin Hematol. 2009; 16(6):453-459 (Invited).

3. Zuckerman T, Ganzel C, Tallman MS, Rowe JM. How I treat hematologic emergencies in

adults with acute leukemia. Blood 2012; 120(10):1993-2002 (Invited).

4. Zuckerman T, Rowe JM. Pathogenesis and prognostication in acute lymphoblastic leukemia.

Oncology | Hematology | Pharmacology & Drug Discovery. F1000Prime Rep. 2014; 8:6:59

(Invited)

5. Henig I, Zuckerman T. Hematopoietic stem cell transplantation – 50 years of evolution and

future perspectives. Rambam Maimonides Med J. 2014; 29:5(4). e0028

6. Zuckerman T, Rowe JM. Transplantation in acute myeloid leukemia. Hematology/Oncology

Clinics of North America 2014; 28(6):983-994 (Invited).

7. Zuckerman T, Beyar-Katz O, Rowe JM. Should autotransplantation in AML CR1 be

revisited? Curr Opin Hematol. 2016; 23(2):88-94 (Invited).

8. Beyar-Katz O, Kruzel Davila E, Zuckerman T, Fineman F, Haddad N, Okasha D, Henig I,

Leiba R, Rowe JM, Ofran Y. Adult nephrotic syndrome after hematopoietic stem cell

transplantation: renal pathology is the best predictor of response to therapy. Biol Blood Marrow

Transplant 2016;22(6):975-981.

9. Lavi N, Rowe JM, Zuckerman T. Allogeneic stem cell transplantation for myelofibrosis. Curr

Opin Hematol. 2017;24(6):475-480 (Invited).

10. Henig I, Rowe J, Hadad N, Fineman R, Benyamini N, Zuckerman T. Hematopoietic stem cell

transplantation in the perspective of time and up to the 2000 transplant at the Rambam Health

Care Campus. Harefuah. 2017;156(9):589-594. Review. Hebrew.

11. Zuckerman T, Rowe JM. Shifting therapeutic paradigms in induction and consolidation for

older adults with acute myeloid leukemia. Curr Opin Hematol. 2019 Mar;26(2):51-57 (Invited).

12. Beyar-Katz O, Bitterman R, Zuckerman T, Ofran Y, Yahav D, Paul M. Anti-herpesvirus

prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant

for haematological disease: systematic review and meta-analysis. Clin Microbiol Infect. 2020

Feb;26(2):189-198.

20

13. Yehudai-Ofir D, Henig I, Zuckerman T. Aberrant B cells, autoimmunity and the benefit of

targeting B cells in chronic graft-versus-host disease. Autoimmun Rev. 2020 Apr;19(4):102493.

14.3 Books

14.4 Book Chapters

1. Zuckerman T, Rowe JM. Chapter 19: Acute leukemia. In: Schmaier AH, Lazarus HM (eds.),

Concise Guide to Hematology, Blackwell Publishing Company. pp. 235-250, 2012.

2. Zuckerman T. Selected CD34+ stem cells for graft engineering. 34 case reports. In: Aversa F,

Kröger N (eds.), Hematopoietic Stem Cell Transplantation, Thieme Verlag, 72 pp, 2014.

3. Zuckerman T, Rowe JM. Acute leukemia. In: O'Sullivan B (ed.), UICC Manual of Clinical

Oncology, 9th

edition, Wiley, 2015.

14.5 Letters to the Editor

1. Avivi I, Fineman R, Haddad N, Katz T, Oren I, Rowe JM, Zuckerman T. Fatal Kaposi

sarcoma after allogeneic stem cell transplantation. Letter to the Editor. Leuk Lymphoma

2011; 52(12):2402-2404.

2. Zuckerman T. Allogeneic transplant: Does age still matter? Inside Blood Commentary

2017; 130(9):1079-1080 (Invited)Nevo N, Zuckerman T, Gur-Cohen S, Kollet O,

Avemaria F, Shpall EJ, Mendt MC, Nagler A, Brenner B, Ben Arush M, Lapidot T. PAR1

Expression Predicts Clinical G-CSF CD34+ HSPC Mobilization and Repopulation Potential

in Transplanted Patients. Hemasphere. 2019 Aug 20;3(5):e288.

4. Ofran Y, Ringelstein-Harlev S, Slouzkey I, Zuckerman T, Yehudai-Ofir D, Henig I, Beyar-

Katz O, Hayun M, Frisch A. Daratumumab for eradication of minimal residual disease in

high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia.

Leukemia 2020 Jan;34(1):293-295

5. Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi

N, Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban

R, Tvito A, Rowe JM, Ganzel C. Bone marrow blast elimination by the fifth day of 7+3

induction is the strongest predictor of potential cure in patients with acute myeloid leukemia

younger than 61 years of age: A long-term follow-up of a multi-center prospective study.

Am J Hematol. 2020 Jan;95(1):E3-E5

6. Benyamini N, Lavi N, Zuckerman T, Aviv A, Rowe JM, Katz T. Newly diagnosed

myeloma patients with low-burden disease may benefit from tandem autologous stem cell

transplantation: results of long-term follow-up. Bone Marrow Transplant. 2019 Sep 16

[Epub ahead of print]

21

7. Shahar Gabay T, Chapal-Ilani N, Moskovitz Y, Biezuner T, Oron B, Brilon Y, Fridman-

Dror A, Sabah R, Balicer R, Tanay A, Mendelson-Cohen N, Dann EJ, Fineman R,

Kaushansky N, Yehudai-Resheff S, Zuckerman T, Shlush LI. Donor cell leukemia:

reappearance of gene mutations in donor cells more than an incidental phenomenon?

Haematologica, 2020 May 7 [Epub ahead of print]

14.6 Refereed Papers in Conference Proceedings

14.7 Patents (granted)

22

14.8 Other publications

1. Ljungman P, de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-

Ortiz MJ, Cordonnier C, Einsele H, Gonzalez-Vicent M, Espigado I, Halter J, Martino R, Mohty

B, Sucak G, Ullmann AJ, Vázquez L, Ward KN, Engelhard D; Outcome of pandemic H1N1

infections in hematopoietic stem cell transplant recipients. Infectious Diseases Working Party,

European Group for Blood and Marrow Transplantation; Infectious Complications

Subcommittee, Spanish Group of Haematopoietic Stem-cell Transplantation. Haematologica.

2011; 96(8):1231-1235.

Collaborators (66): Abecasis M, Ahmed A, Batle Massana M, Carrascosa Vallejo T, Castagna

L, Cordonnier C, Cudillo L, Dammann E, de la Camara R, Cannata-Ortiz J, García Noblejas

A, de las Heras N, de la Rubia J, Dengel W, Devos A, Einsele H, Engelhard D,Or R, Espigado

I, de la Cruz-Vicente F, Finke J, Girmenia C, Gaertner J, Gonzalez-Vicent M, Lassaletta

Á, Grassi A,Patriño Guiterrez B, Halter J, Hirsch H, Helweg M, Holler E, Itälä-Remes

M, Leveille S, Ljungman P, Perez-Bercoff L, López J, Maertens J, Martínez J, Martino

R, Mohty B, Monserrat J, Nieto Campuzano JB, Heras I, Meseguer M, Petersen H,Rovira

M, Ruiz I, Olivé T, Sedlacek P, Serrano D, Severino A, Sica S, Sonet A, Spyridonidis

A, Styczynski J, Sucak G,Takács K, Theuser C, Topoglu P, Ullmann A, Vallejo C, Vázquez

L, Wahlin A, van der Wal T, Ward KN, Zuckerman T.

2. Bierings M, Bonfim C, Peffault De Latour R, Aljurf M, Mehta PA, Knol C, Boulad F, Tbakhi

A, Esquirol A, McQuaker G, Sucak GA, Othman TB, Halkes CJM, Carpenter B, Niederwieser

D, Zecca M, Kröger N, Michallet M, Risitano AM, Ehninger G, Porcher R, Dufour C; EBMT

SAA WP.Transplant results in adults with Fanconi anaemia. Br J Haematol. 2018;180(1):100-

109.

Collaborators (67): Bonfirm C, Socié G, Gurman G, Ghavamzadeh A, Hamladji RM, van Lint

MT, Stepensky P, Koh M, Ozkurt ZN, Veelken JH, Bunjes D, Beelen D, Campos A, Robinson

S, Alessandrino EP, Unal A, Fernandez Navarro JM, Mufti GJ, Velardi A, Passweg J, Apperley

J, Sengeloev H, Ljungman P, Foá R, Alegre A, Espiga CR, Cornelissen JJ, Di Bartolomeo

P, Cordonnier C, Browne P, Jubert C, Gastl G, Pierelli L, Johansson JE, Fagioli F, Moraleda

J, Zuckerman T, Bazarbachi A, Sedlacek P, Rössig C, Wynn RF, Hallek M, Toren A, Zudaire

T, Clausen J, Spencer A, Grazon Lopez S, Schots R, Komarnicki M, González Muniz S, Vitek

A, Rambaldi A, Merli F, Rubio MT, Rossig C, Cabrera Marín JR, Porto F, Kerre T, Metzner

B, Stein J, Bertrand Y, Ciceri F, Chybicka A, Diez-Martin JL, Bayoumy M, de la Fuente

J, Fegueux N.

23

15. CONFERENCES

15.1 Plenary, Keynote or Invited Talks

International

1. Cell therapy for immunity. 6th

International Symposium: Haploidentical Stem Cell

Transplantation, Jerusalem, Israel, September 2010 (plenary).

2. Acute lymphocytic leukemia. XXXIII World Congress of the International Society of

Hematology, Jerusalem, Israel, October 2010 (plenary).

3. Autologous transplantation. Leukemia Working Party Symposium – Therapeutic options in

early AML at high risk: ALWP meets EU trial groups, ASCT GROUP, Milan, Italy, November

13. 2010 (plenary).

4. Stem cell transplantation in AML. How can we further improve? Innovations in Hematology,

Haifa, Israel, July 3, 2014 (plenary).

NATIONAL

1. Haploidentical SCT – debate. Israel Society of Hematology and Blood Transfusion – Winter

Meeting, Tel Aviv, February 2008 (plenary).

2. New molecular markers in the diagnosis of AML. Leukemia Forum within the Israeli Society

of Hematology, Tel Aviv, January 2011 (plenary).

3. Stem cell transplantation in cutaneous T-cell lymphoma. Israeli Society of Dermatology,

Rambam Health Care Campus, February 2013 (Keynote).

4. Stem cell transplantation using umbilical cord blood. Annual Meeting of the Israel Society of

Hematology and Blood Transfusion, Dead Sea, October-November 2014 (Chairperson).

5. BMT in lymphoma and CLL. Israeli Cancer Association Patients Meeting, Tel Aviv, May

2014.

6. Allogeneic stem cell transplantation in AML: to whom, when and how? Leukemia Forum

within the Israeli Society of Hematology, Tel Aviv, November 2014 (plenary).

24

15.2 Contributed Talks and Posters

International

1. Zuckerman E, Lanir A, Sabo E, Rosenvald-Zuckerman T, Matter I, Eldar S, Yeshurun D. CA-

125 as a marker for detection and quantitation of ascites in liver cirrhosis. 46th

Annual Meeting

of the American Association for the Study of Liver Diseases, Chicago, USA, November 3-7,

1995. Hepatology 1995; 22:163A (poster presentation).

2. Rosenvald-Zuckerman T, Yasmin S, Retzios A, Kasper CK, Liebman HA. Kinetics of factor

IX activity differ from that of factor IX antigen in patients with hemophilia B. Thirty-seventh

annual meeting of the American Society of Hematology, Seattle, WA, December 1995. Blood

1995; 86(10); supp 1:886A (poster presentation).

3. Rosenvald-Zuckerman T, Zuckerman E, Duer D, Fong T-L, Dian GD, Levine A.

Hepatitis C infection in patients with non-Hodgkin B-cell lymphoma. 38th

Annual Meeting of

the American Society of Hematology, Orlando, USA, December 6-10, 1996. Blood 1996; 88

(supp. 1):222a (poster presentation).

4. Zuckerman T, Zuckerman E, Duer D, Fong T-L, Dian GD, Levine. Liver function in HCV

infected patients with hematological malignancies treated with chemotherapy. 38th

Annual

Meeting of the American Society of Hematology, Orlando, USA, December 6-10, 1996. Blood

1996; 88 (supp. 1):222a (poster presentation).

5. Levine MA, Zuckerman E, Zuckerman T, Nelson R, Govindrajan S, Valinluck B, Bernstein L.

Lack of association between hepatitis C infection and development of AIDS related lymphoma.

39th

Annual Meeting of the American Society of Hematology, San Diego, USA, December 5-9,

1997. Blood 1997; (suppl) (poster presentation).

6. Zuckerman T, Sahar D, Streichman S, Attias D, Eldar I, Rowe JM, Zuckerman E.

BCL2 and immunoglobulin gene rearrangement in patients with hepatitis C virus (HCV)

infection. 40th

Annual Meeting of the American Society of Hematology, Miami Beach, USA

December 1998. Blood 1998; 92(10; suppl 1) 1673a (poster presentation).

7. Dann EJ, Avivi I, Shechter Y, Haddad N, Zuckerman T, Hoffman R, Brenner B, Rowe JM.

Aprotinin as an adjunct to platelets and tranexamic acid in life-threatening bleeding post bone

marrow transplantation. 41st Annual Meeting of the American Society of Hematology, New

Orleans, USA, December 1999. Blood 1999; 94(suppl1):1488a (poster presentation).

8. Zuckerman T, Zuckerman E, Sahar D, Hertz E, Mandel R, Sabo E, Streichman S, Rowe JM.

The effect of anti-viral treatment on (14;18) translocation and immunoglobulin gene

rearrangement in patients with chronic hematitis C virus (HCV) infection. 41st Annual Meeting

25

of the American Society of Hematology, New Orleans, USA, December 1999. Blood 1999;

94(suppl 1):1711a (oral presentation).

9. Zuckerman T, Avivi I, Gavish I, Haddad N, Ben-Yehuda I, Dann EJ, Hoffer E, Rowe JM,

Brenner B. Veno-occlusive disease (VOD) following stem cell transplantation: role of

defibrotide treatment. 26th

Annual Meeting of the European Group for Blood and Marrow

Transplantation (EBMT), Innsbruck, Austria, March 2000. Bone Marrow Transplantation 2000;

25(suppl 1) 894a (oral presentation).

10. Avivi I, Haddad N, Zuckerman T, Hoffman R, Arbov L, Gavish I, Ben-Arieh Y, Oren I, Rowe

JM, Dann EJ. Prior fungal infection is not a contraindication to bone marrow transplantation

(BMT). 5th

Annual Meeting of the European Haematology Association, Birmingham, UK, June

2000. The Haematology Journal 2000; 1(suppl 1)854a (oral presentation).

11. Rosenbaum H, Gavish I, Avivi I, Haddad N, Hoffman R, Bennett M, Albov L, Nadir Y,

Zuckerman T, Dann EJ, Fineman R, Katz T, Faibish Y, Brenner B, Carter A, Rowe JM.

Autologous peripheral blood stem cell transplantation (PBSCT) in multiple myeloma (MM):

results in 38 patients. 5th

Annual Meeting of the European Haematology Association,

Birmingham, UK, June 2000, The Haematology Journal 2000; 1(suppl 1)813a (oral

presentation).

12. Haddad N, Zuckerman T, Katz T, Oliven A, Arbov L, Gavish I, Reisner Y,

Rowe JM. Allogeneic BMT for CML using T-cell depletion and megadoses of CD34 cells:

potential for reduced toxicity without loss of efficacy? 42nd

Annual Meeting of the American

Society of Hematology, San Francisco, USA, December, 2000. Blood 2000; 96; 607a (oral

presentation).

13. Zuckerman T, Gavish I, Avivi I, Eran A, Ben-Yehuda I, Sabo E, Lanir N,

Rowe JM, Brenner B. Predictive model for the development of veno occlusive disease (VOD)

following stem cell transplantation (SCT). 42nd

Annual Meeting of the American Society of

Hematology, San Francisco, USA, December 2000. Blood 2000; 96; 1676a (oral presentation).

14. Dann EJ, Drumea K, Haddad N, Hoffman R, Fineman R, Arbuv L, Rosenbaum H,

Zuckerman T, Ben-Shachar M, Haim N, Epelbaum R, Rowe JM. High-dose

cyclophosphamide (CTX) in CHOP regimen is safe and efficacious for aggressive non-Hodgkin

lymphoma. 43rd

Annual Meeting of American Society of Hematology, Orlando, USA,

December 2001. Blood 2001; 89; 1464a (oral presentation).

15. Zuckerman T, Haddad N, Elhasid R, Rowe JM. Haploidentical transplantation: a

single center experience. 2nd

European Workshop on Haploidentical Stem Cell Transplantation,

Perugia, Italy, October 2000. Leukemia 2002; 16; 417a (oral presentation).

26

16. Zuckerman T, Rubin D, Gideoni O, Haddad N, Sabo E, Rowe JM, Brenner B,

Pollack S. Assessment of cytokine gene polymorphism in patients developing

hepatic veno occlusive disease following stem cell transplantation. 28th

Meeting of the European

Group for Blood and Marrow Transplantation (EBMT), Monteux, Switzerland, March 2002.

Bone Marrow Transplantation 2002; 29 (Suppl. 2); 723a (oral presentation).

17. Haddad N, Katz T, Zuckerman T, Elhasid R, Fineman R, Shechter Y, Arbov L, Hoffman R,

Rosenbaum H, Nadir Y, Brenner B, Rowe JM. Haploidentical transplantation for acute

myelogenous leukemia. 3rd European Workshop on Haploidentical Stem Cell Transplantation,

Perugia, Orvieto, June 28-29, 2002 (oral presentation).

18. Zuckerman T, Katz T, Haddad N, Faibish Y, Fineman R, Dann EJ, Rowe JM. CD34-selected

stem cell boost for poor graft function following allogeneic stem cell transplantation. 29th

Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT),

Istanbul, Turkey, July 2003. Bone Marrow Transplantation 2003; 31(Suppl. 1):721a (oral

presentation).

19. Haddad N, Katz T, Zuckerman T, Fineman R, Dally N, Olivan A, Shechter Y, Elhasid R,

Rowe JM. Post-transplant immune hemolytic anemia associated with T-cell depletion and

presence of immature B-cell fraction. 29th

Annual Meeting of the European Group for Blood

and Marrow Transplantation (EBMT), Istanbul, Turkey, July, 2003. Bone Marrow

Transplantation 2003; 31(Suppl. 1):814a (oral presentation).

20. Wolf DG, Lurain NS, Zuckerman T, Hoffman R, Satinger J, Honigman A, Saleh N, Robert ES,

Rowe JM, Kra-Oz Z. Emergence of late cytomegalovirus central nervous system disease in

hematopoietic stem cell transplant recipients. 29th

Annual Meeting of the European Group for

Blood and Marrow Transplantation, Istanbul, Turkey, July 2003. BMT 2003; 31(suppl 1):p467

(oral presentation).

21. Dann EJ,Yigla M, Avivi I, Haddad N, Fineman R, Zuckerman T, Hoffman R, Brenner B,

Rowe JM. Aprotinin and tranexamic acid ((AMCA) as an adjunct to high-dose steroids in the

management of diffuse alveolar hemorrhage in patients with hematological malignancies. 45th

Annual Meeting of the American Society of Hematology. San Diego, USA, December 2003.

Blood 2003; 104(11):1713a (oral presentation).

22. Zuckerman T, Bouskila G, Bonstein L, Lanir N, Toubi A, Toubi E, Groshar D, Zuckerman E.

Mechanism of thrombocytopenia in patients with cirrhosis: the role of functional spleen volume,

serum thrombopoietin levels. 45th

Annual Meeting of the American Society of Hematology, San

Diego, USA, December 6-9, 2003 (oral presentation).

23. Haddad N, Katz T, Fineman R, Oliven A, Ballan M, Avivi I, Hoffman R, Dann EJ, Arbov L,

Faibish T, Zuckerman T, Rowe JM. Allogeneic BMT for CML using partial T-cell depletion

27

and no post-transplant GvHD prophylaxis – an effective regimen with reduced toxicity: 31

patients treated in a single institution. 45th

Annual Meeting of the American Society of

Hematology, San Diego, USA, December 2003. Blood 2003; 104(11):2625a (oral presentation).

24. Katz T, Haddad N, Zuckerman T, Fineman R, Avivi I, Oliven A, Rowe JM. Obesity or

underweight: which is safer in stem cell transplantation? Thirtieth Annual Meeting of the

European Group for Blood and Marrow Transplantation (EBMT). Barcelona, Spain, March

2004. Oral presentation) Bone Marrow Transplantation 33 (Suppl. 1):386a, 2004.

25. Dann EJ, Badian E, Avivi I, Haddad N, Stravets T, Fineman R, Bonstein L, Olivan A, Kertsman

E, Zuckerman T, Rowe JM. Extracorporeal photochemotherapy for acute and chronic GvHD, a

single-center report of 43 patients. 30th

Annual Meeting of the European Group for Blood and

Marrow Transplantation (EBMT), Barcelona, Spain, March 2004. Bone Marrow

Transplantation 2004; 33(Suppl. 1):700a (oral presentation).

26. Haddad N, Katz T, Elhasid R, Zuckerman T, Avivi I, Schechter Y, Fineman R, Rosenbaum H,

Hoffman R, Brenner B, Akria L, Dally N, Nadir I, Dann EJ, Faibish T, Oliven A, Zaidman I,

Arbov L, Ben-Arush M, Etzioni A, Reisner Y, Rowe JM. Sixty consecutive haploidentical

transplants in adults and children: a single center experience. 4th

International Workshop on

Haploidentical Transplants, Naples, Italy, July 2004 (oral presentation).

27. Zuckerman T, Ben Harush S, Avivi I, Gavish I, Haddad N, Fineman R, Dann E, Hoffman R,

Brenner B, Rowe JM, Zuckerman E. CA-125 as a marker for the early diagnosis of hepatic

veno-occlussive disease following hematopoietic stem cell transplantation. 46th

Annual Meeting

of the American Society of Hematology, San Diego, USA, December 2004. Blood 2004; 104;

1138a (poster presentation).

28. Katz T, Zuckerman T, Haddad N, Fineman R, Dann EJ, Oliven A, Avivi I, Rowe JM. Does

preemptive escalated donor lymphocyte infusion following allogeneic stem cell transplantation

in CML succeed to provide long-term remission? 31st Annual Meeting of the European Group

for Blood and Marrow Transplantation (EBMT), Prague, Czech Republic, March 2005. Bone

Marrow Transplantation 2005; 35(Suppl. 2):595a (poster presentation).

29. Haddad N, Elhasid R, Fineman R, Avivi I, Zuckerman T, Zaidman I, Ben Arush M, Gidoni O,

Kraoz Z, Rowe JM. Genetic predisposition and CMV infection in allogeneic bone marrow

transplantations. 31st Annual Meeting of the European Group for Blood and Marrow

Transplantation (EBMT), Prague, Czech Republic, March 2005. Bone Marrow Transplantation

2005; 35(Suppl. 2):650a (poster presentation).

30. Zuckerman T, Haddad N, Avivi I, Fineman R, Oliven A, Dann EJ, Katz T, Rowe JM.

Haploidentical transplantation for severe aplastic anemia. 31st Annual Meeting of the European

28

Group for Blood and Marrow Transplantation (EBMT), Prague, Czech Republic, March 2005.

Bone Marrow Transplantation 2005; (Suppl. 2);783a (oral presentation).

31. Dann EJ, Bar-Shalom R, Haim N, Tamir A, Ben-Shachar M, Avivi I, Zuckerman T,

Kirschbaum M, Goor O, Libster D,

Rowe JM, Epelbaum R. Risk adapted BEACOPP regimen

based on early scintigraphy can reduce the cumulative dose of chemotherapy for standard and

high risk Hodgkin Lymphoma (HD) with no impairment of outcome. 47th

Annual Meeting of

the American Society of Hematology, Atlanta, USA, December 2005. Blood 2005; 106:240a

(oral presentation).

32. Haddad N, Fineman R, Avivi I, Zuckerman T, Akria A, Faibish T, Markovitz M, Dan L, Abu

Zemach D, Elhasid R, Rowe JM. Relapse of acute leukemia after allogeneic hematopoietic stem

cell transplantation, patient characteristics and clinical course: A single center experience. 32nd

Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT),

Hamburg, Germany, March 2006. Bone Marrow Transplantation 2006; 37(Suppl. 1):566a,

(poster presentation).

33. Elhasid R, Ben-Arush M, Postovsky S, Ben Barak A, Zaidman I, Haddad N, Zukerman T,

Rowe JM. Mismatched related allogeneic bone marrow transplantation in patients with Fanconi

anemia. 32nd

Annual Meeting of the European Group for Blood and Marrow Transplantation

(EBMT), Hamburg, Germany, March 2006. Bone Marrow Transplantation 2006; 37(Suppl.

1):574a, (poster presentation).

34. Caspi O, Avivi I, Gavish I, Haddad N, Fineman R, Rowe JM, Zuckerman T. Engraftment

syndrome in patients undergoing hematopoietic stem cell transplantation and role of IL2

receptor. 32nd

Annual Meeting of the European Group for Blood and Marrow Transplantation

(EBMT), Hamburg, Germany, March 2006. Bone Marrow Transplantation 2006; 37(Suppl.

1):907a (poster presentation).

35. Zuckerman T, Katz T, Haddad N, Fineman R, Avivi I, Dann EJ, Sahar D, Oliven A, Hertz E,

Ofran Y, Akria L, Markovitz M, Faibish T, Rowe JM. Allogeneic Stem Cell Transplantation

(ASCT) in CML with partial t-cell depletion, no prophylaxis for Graft-Versus-Host Disease

(GvHD) and preemptive DLI for patients with post-transplant Minimal Residual Disease

(MRD): an alternative approach in CML transplantation with low morbidity and long term

disease free survival. 48th

Annual Meeting of the American Society of Hematology, Orlando,

USA, December 2006. Blood 2006; 108:98a (oral presentation).

36. Chermesh I, Efergan R, Alpert E, Tach N, Zuckerman T, Hadad S. Olive based lipid (clinoleic)

emulsion for patients who develop bone pain secondary to an MCT/LCT (lipofundin) lipid

emulsion. 29th

ESPEN Congress, Prague, Czech Republic, September 2007 (oral presentation).

29

37. Avivi I, Avraham S, Koren-Miachelovitz M, Zuckerman T, Nagler A, Rowe JM, Nagler R.

The effects of high-dose therapy on salivary profile and oral integrity in myeloma patients

undergoing autologous stem cell transplantation. 34th

Annual Meeting of the European Group

for Blood and Marrow Transplantation (EBMT), Florence, Italy, March 2008. Bone Marrow

Transplantation 2008; 41(Suppl. 1):86a, (oral presentation).

38. Zuckerman T, Benyamini N, Haddad N, Fineman R, Avivi I, Sabo E, Rowe JM , Oren I.

Emergence of uncommon infection in bone marrow transplantation: the modern Trojan horse?

35th

Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT),

Göteborg, Sweden, March 2009. Bone Marrow Transplantation 2009; 43(Suppl. 1s):884 (oral

presentation).

39. Dann EJ, Badian A, Stravets T, Kertsman E, Phenklbaum S, Zuckerman T, Haddad N, Elhasid

R, Bonstein L, Rowe J.M. Extracorporeal photochemotherapy for acute and chronic GVHD, a

report of 102 patients treated in a single institution. 14th

Congress of the European Hematology

Association, Berlin, Germany, June 2009. Haematologica 2009; 94, 0550a (oral presentation).

40. Elhasid R, Zaidman I, Khalil A, Zuckerman T, Haddad N, Katz T, Ben Arush M, Rowe JM.

Allogeneic stem cell transplantation in congenital hemoglobinopathies – a curative approach

when performed as a primary therapeutic modality: a single center experience. 51st Annual

Meeting of the American Society of Hematology, New Orleans, USA, December 2009. Blood

2009; 114:1144a (poster presentation).

41. Dann E, Bar-Shalom R, Tamir A, Ben-Shachar M, Avivi I, Zuckerman T, Haddad N,

Rosenbaum H, Fineman R, Goor O, Libster D, Blumenfeld Z, Rowe JM, Epelbaum R. For

standard and high-risk patients with Hodgkin lymphoma six cycles of tailored BEACOPP,

Based on interim scintigraphy, are effective and female fertility is preserved. 51st Annual

Meeting of the American Society of Hematology, New Orleans, USA, December 2009. Blood

2009; 114: 1552a (oral presentation).

42. Shouval R, Shlush LI, Ali S, Shapiro E, Rowe JM, Zuckerman T. FLT3 mutation in single

leukemic cells – more than meets the eye. 33rd

World Congress of the International Society of

Hematology, Jerusalem, October 2010 (oral presentation).

43. Shlush LI, Chapal N, Adar R, Izraeli S, Rowe JM, Skorecki K, Shapiro E, Zuckerman T.

Single-cell phylogenetic analysis provides novel insight into resistance mechanisms in AML.

52nd

Annual Meeting of the American Society of Hematology, Orlando, USA, December 2010.

Blood 2010; 116:178a (oral presentation).

44. Haddad N, Fineman R, Zuckerman T, Rowe JM. Post-engraftment persistent leukocytosis may

be an independent poor prognostic factor in allogeneic stem cell transplant patients. 53rd

Annual

30

Meeting of the American Society of Hematology, San Francisco, USA, December 2011. Blood

2011; 118:4574 (oral presentation).

45. Beyar-Katz O, Haddad N, Fineman R, Ofran Y, Henig I, Lavi N, Sabo E, Rowe JM,

Zuckerman T. Outcome of favorable acute myeloid leukemia is improved following

autologous stem cell transplantation in first complete remission. 38th

Annual Meeting of the

European Group for Blood and Marrow Transplantation, Geneva, Switzerland, April 1-4, 2012.

Bone Marrow Transplantation 2012; 47(Suppl. 1s):402 (oral presentation).

46. Horowitz N, Wittmann T, Rowe JM, Zuckerman T, Avivi I. Similar Frequency and types of

neurological complications in patients undergoing matched related and matched unrelated donor

stem cell transplantation for hematological malignancies. 54th

ASH Annual Meeting, Atlanta,

USA, December 2012. Blood 2012; 120:4515 (poster presentation).

47. Yeshurun M, Ram R, Shpilberg O, Hershkovitzi C, Vidal L, Zuckerman T, Haddad N, Rowe

JM, Yerushalmi R, Nagler A and Shimoni A. Female donor allografts have a higher CD3

content than male donor allografts – potential impact on transplantation outcomes in male

recipients. 54th

ASH Annual Meeting, Atlanta, USA, December 2012. Blood 2012; 120:587

(poster presentation).

48. Avivi I, Wittman T, Benyamini N, Kra-Oz Z, Szwrcwort M, Oren I, Rowe JM, Henig I,

Zuckerman T, Horowitz N. reactivation of IC virus in 171 allografted patients: incidence and

clinical significance. 54th

ASH Annual Meeting, Atlanta, USA, December 2012.

Blood 2012; 120:4148 (poster presentation).

49. Avivi I, Wittmann T, Benyamini N, Kra-Oz Z, Szwarcwort M, Oren I, Rowe JM, Zuckerman

T, Horowitz N. Preemptive detection of JC Virus in peripheral blood of patients undergoing

allogeneic stem cell transplantation: a potential tool to prevent progressive multifocal

leukoencephalopathy in high-risk patients? 55th

ASH Annual Meeting and Exposition, New

Orleans, USA, December 2013. Blood 2013; 122(21):4537 (poster presentation).

50. Vadas Z, Ganon-Elazar E, Nov Y, Henig I, Haj T, Attias D, Haddad N, Fineman R, Rowe

JM, Zuckerman T. Semaphorin 3A expression on donor and recipient regulatory cells: a novel

pre-transplant biomarker predicting the development of acute graft-versus-host disease. 56th

ASH Annual Meeting and Exposition, San Francisco, USA, December 2014, Blood 2014;

124(21): 3935 (poster presentation).

51. Glik A, Bonstein L, Atwah N, Ganon-Elazar E, Henig I, Haddad N, Fineman R, Rowe

JM, Zuckerman T. Stable blood group chimerism in recipients of ABO incompatible

allogeneic stem cell transplantation. 56th

ASH Annual Meeting and Exposition,

San Francisco, USA, December 2014, Blood 2014; 124(21):1553 (poster presentation).

31

52. Cohen YC, Zuckerman T, Yeshurun M, Perez G, Magen H, Henig I, Levi I, Shargian L,

Trestman S, Rouvio U, Naparstek E, Ganon-Elazar E, Avivi I, Ram R. Efficacy and safety of

autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a

retrospective Israeli multi-site cohort study. 56th

ASH Annual Meeting and Exposition, San

Francisco, USA, December 2014. Blood 2014; 124(21):3989 (poster presentation).

53. Mevorach D, Zuckerman T, Or R, Nagler A, Rowe JM, Shimoni A, Reiner I. Early apoptotic

cells (ApoCell) as prophylaxis of graft-versus-host disease is safe and effective: 1 year follow-

up and mechanism of action. 2015 BMT Tandem Meeting, San Diego, USA, February 11-15,

2015 (oral presentation).

54. Yehudai D, Henig I, Zaidman I, Mandel-Shorer N, Gefen A, Zuckerman T. Altered defibrotide

treatment regimen for veno-occlusive disease: a single center experience. 3rd

Annual Meeting of

the Society of Hematologic Oncology (SOHO), Houston, USA, September 16-19, 2015 (poster

presentation).

55. Zuckerman T, Gengrinovitch S, Ben Yakar R, Ron Hoffman R, Henig I, Lavi N, Akria L,

Ofran Y, Nudelman O, Martin S. Tallman MS, Rowe JM. Astarabine, a pro-drug of Cytarabine,

is safe for patients with advanced acute leukemia. a Phase I/IIa single center study in

relapsed/refractory or medically unfit patients. 57th

ASH Annual Meeting and Exposition,

Orlando, USA, December 2014, Blood 2014; 124(21):3810 (poster presentation).

56. Yehudai-Resheff S, Attias S, Zuckerman T. How do bone microenvironment cells support

AML progression? Unraveling the diverse interactions of single leukemic cells with their

original niche. The Tumour Microenvironment in the Haematological Malignancies and its

Therapeutic Targeting, Lisbon, Portugal, May 7-9, 2015 (poster presentation).

57. Meiron M, Pinkas L, Levi H, Katz T, M. Rowe JM, Ganon E, Zuckerman T. Prevention of

acute GvHD following negative functional selection of allogeneic T-Cells using Fas ligand

exposure of the graft: preliminary results for launching a clinical study. 57th

ASH Annual

Meeting and Exposition, Orlando, USA, December 2014. Blood 2015; 126:3084 (poster

presentation).

58. Claude Gorin N, Labopin M, Czerw T, Leibundgut K, Blaise D, Yves Dumas P, Nemet D,

Arcese W, Foa R, Depei W, Huynh A, Zuckerman T, Meijer E, Cagirgan S, Cornelissen J,

Mohty M, Nagler A. Autologous stem cell transplantation for adult acute myelocytic leukemia

in first remission: better outcome following Busulfan and Melphalan compared to Busulfan and

Cyclophosphamide: a retrospective study from the acute leukemia working party of the EBMT.

57th

ASH Annual Meeting and Exposition, Orlando, USA, December 2014. Blood 2015;

126:926 (oral presentation).

32

59. Gengrinovitch S, Ben Yakar R, Zuckerman T, Krivoy N, Rowe JM. Astarabine, a Cytarabine

pro-drug, is safe and efficacious in the treatment of leukemia – results of animal studies. 57th

ASH Annual Meeting and Exposition, Orlando, USA December 4, 2014. Blood 2015; 126:2545

(poster presentation).

60. Duarte RF, Ariane Boumendil A, Onida F, Finel H, Gabriel IH, Arcese W, Browne P, Beelen

DW, Kobbe G, Veelken JH, Arranz R, Greinix HT, Lenhoff S, Poiré X, Ribera J, Thompson J,

Zuckerman T, Mufti GJ, Cortelezzi A, Olavarria E, Sureda A, Dreger P. Allogeneic

hematopoietic cell transplantation (HCT) for advanced mycosis fungoides and Sezary syndrome

(MF/SS): impact of increasing the use of unrelated donors (UD) – the EBMT lymphoma

working party experience. 57th

ASH Annual Meeting and Exposition, Orlando, USA, December

2014. Blood 2015; 126:4403 (poster presentation).

61. Meiron M, Pinkas L, Levi H, Rodinov G, Yarkoni S, Katz T, Rowe JM, Ganon E, Zuckerman

T. Pre-transplant treatment of hematopoietic grafts with Fas Ligand for acute graft-versus-host

disease prevention: preliminary results for launching a clinical study. 42nd

Annual Meeting of

the European Society for Blood and Marrow Transplantation, Valencia, Spain, April 3-6, 2016

(poster presentation).

62. Zuckerman T, Yehudai D, Henig I, Zaidman I, Mandel-Shorer N, Gefen A. Altered defibrotide

treatment regimen for veno-occlusive disease: a single center experience. 42nd

Annual Meeting

of the European Society for Blood and Marrow Transplantation, April 3-6, 2016, Valencia,

Spain (oral presentation)

63. Basin J, Katzir L, Tamari Lapid N, Benyakov O, Zuckerman T. Support and information group

for patients and their families in bone marrow transplant unit. 42nd

Annual Meeting of the

European Society for Blood and Marrow Transplantation, April 3-6, 2016, Valencia, Spain

(poster presentation).

64. Yehudai-Reshef S, Attias S, Gabay T, Sabah R, and Zuckerman T. Bone Marrow Stromal

Cells Derived at Diagnosis and Remission Preferentially Support AML Cell Proliferation in

Vitro. 58th

ASH Annual Meeting and Exposition, San-Diego, USA, December 2016. Blood

2017; 128:1492 (poster presentation).

65. Zuckerman T, Gengrinovitch S, Ben-Yakar R, Hoffman R, Henig I, Lavi N, Akria L, Ofran Y,

Horowitz NA, Nudelman O, Koren-Michowitz M, Yeganeh S, Tallman MS, and Rowe JM.

Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the

Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of

an Ongoing Phase I/IIa Study. 58th

ASH Annual Meeting and Exposition, San-Diego, USA,

December 2016. Blood 2017; 128:1650 (poster presentation).

33

66. Poiré X, Labopin M, Blaise D, Chevallier P, Maertens J, Deconinck E, Forcade E, Rambaldi A,

Baerlocher GM, Zuckerman T, Volin L, Schouten HC, Ifrah N, Esteve J, Mohty M, and Nagler A.

utologous Versus Related Versus Unrelated Hematopoietic Stem Cell Transplantation for Adult

Patients with NPM1 Mutated/FLT3-ITD Negative Acute Myeloid Leukemia in First Remission: A

Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and

Marrow Transplantation (EBMT). 58th

ASH Annual Meeting and Exposition, San-Diego, USA,

December 2016. Blood 2017; 128: 2279 (poster presentation).

67. Nevo N, Gur-Cohen S, Kollet O, Avemaria F, Avci S, Itkin T, Chakrabarty S, Zuckerman T,

Brenner B, Nadir Y, Zaidman I, Ben Arush M, Esmon C, Ruf W, and Lapidot T. Inverse PAR1

Activity of Hematopoietic Stem Cells and BM Stromal Cells Mediates G-CSF-Induced

Mobilization By Regulation of Nitric Oxide Generation. 58th

ASH Annual Meeting and Exposition,

San-Diego, USA, December 2016. Blood 2017; 128: 3370 (poster presentation).

68. Frisch A, Leiba R, Ganzel C, Zuckerman T, Haddad N, Fineman R, and Ofran Y. Prognosis of

Patients with Standard- or Intermediate-Risk Acute Myeloid Leukemia Presenting with Residual

Disease after One Induction Cycle Is Improved If Remission Is Achieved Following Re-Induction

Given By Day 14 Compared to Second-Line Therapy Given 24-40 Days after Induction. 58th

ASH

Annual Meeting and Exposition, San-Diego, USA, December 2016. Blood 2017; 128: 3999 (poster

presentation).

69. Averbuch D, Engelhard D, Tridello G, Hoek J, Wu D, Bierings M, Pirumova V, Graphakos S,

Calore E, Keslova P, Henrik H, Gozdzik J, O’Brien T, Shaw PJ, Groll A, Lanino E, Matthes-Martin

S, Rascon J, Xhaard A, Ljungman P, Zuckerman T, Rojas R, Vrhovac R, Küpesiz A, Perruccio K,

Porta F, Nigro LL, Ziino O, Mikulska M, Styczynski J, Cesaro S. Gram-negative bacteremia in

children after allogeneic hematopoietic stem cell transplantation (HSCT): a multinational study on

behalf of Infectious Diseases Working Party of European Society for Blood and Marrow Transplant

(EBMT-IDWP). 43rd Annual Meeting of the European Society for Blood and Marrow

Transplantation, March 26–29, 2017, Marseille, France. (oral presentation)

70. Poiré X, Labopin M, Blaise D, Chevallier P, Maertens J, Deconinck E, Forcade E, Rambaldi A,

Baerlocher G, Zuckerman T, Volin L, Schouten H, Ifrah N, Esteve J, Mohty M, Nagler A.

Autologous versus related versus unrelated hematopoietic stem cell transplantation for adult

patients with NPM1 mutated/FLT3-ITD negative acute myeloid leukemia in first remission: a study

from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow

Transplantation (EBMT). 43rd Annual Meeting of the European Society for Blood and Marrow

Transplantation, March 26–29, 2017, Marseille, France. (oral presentation).

34

71. Pinkas L, Rodionov G, Katz T, Ganon E, Pereg Y, Rowe JM and Zuckerman T. ApoGraft, a

Negative Functional Selection of Mature T-Cells by Short Ex-Vivo Exposure of Mobilized

Peripheral Blood Graft to Fas Ligand: A Novel Technology for GVHD Prevention. 43rd Annual

Meeting of the European Society for Blood and Marrow Transplantation, March 26–29, 2017,

Marseille, France. (Poster presentation).

72. Raj K, Olavarria E, Eikema DJ, Blok HJ, Bregante S, Ciceri F, Passweg J, Ljungmann P, Schaap

M, Carlson K, Zuckerman T, Volin L, Koc Y, Diez-Martin J, Brossart P, Blaise D, Natale A,

Vitek A, Mclornan D, Robin M, Chalandon Y, Kroger N. Family mismatched allogeneic stem cell

transplantation for myelofibrosis: Report from the Chronic Malignancies Working Party of EBMT.

43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, March 26–

29, 2017, Marseille, France. (Poster presentation).

73. Katzir L, Barhad R, Zuckerman T. Outdoor physical activity for hematological patients. Does it

improve quality of life? 43rd Annual Meeting of the European Society for Blood and Marrow

Transplantation, March 26–29, 2017, Marseille, France. (Poster presentation).

74. Lavi N, Ram R, Yeshurun M, Amit O, Shargian L, Horowitz NA, Zuckerman T. Efficacy and

toxicity of BEAC versus BEAM high-dose chemotherapy in patients with mantle cell lymphoma

undergoing autologous stem cell transplantation. 43rd Annual Meeting of the European Society for

Blood and Marrow Transplantation, March 26–29, 2017, Marseille, France. (Poster presentation).

75. Zuckerman T, Ram R, Koren-Michowitz M, Akria L, Hoffman Henig I, Ofran Y, Lavi N,

Horowitz NA, Nudelman O, Yeganeh S, Gengrinovitch S, Flaishon L, Ben Yakar R, Rowe JM.

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose

Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study. 59 th

ASH

Annual Meeting and Exposition, December 9-12, 2017. Atlanta, GA, USA. Blood 2017, 130, Suppl

1: 893. Oral presentation.

76. Paviglianiti A, Tozatto-Maio K, Rocha V, Gehlkopf E, Milpied N, Esquirol A, Chevallier P, Blaise

D, Damaj G, Nguyen-Quoc S, Cahn JY, Abecasis M, Zuckerman T, Schouten HC, Gurman G,

Rubio MT, Beguin Y, Lopez Corral L, Nagler A, Snowden JA, Yener K, Mordini N, Bonifazi F,

Fanin R, Volt F, Kenzey C, Robinson S, Montoto S, Gluckman E and Ruggeri A. 3318 Outcomes

of Cord Blood Transplantation for Adult Patients with Hodgkin Lymphoma, a Eurocord and EBMT

Lymphoma Working Party Study. 59 th

ASH Annual Meeting and Exposition, December 9-12,

2017. Atlanta, GA, USA. Blood 2017, 130, Suppl 1: 3318. Poster presentation.

77. Kroeger N, Eikema DJ, Knelange NS, Koc Y, Moraleda JM, Dreger P, Schouten HC, Kanz L,

Tischer J, Corradini P, Veelken H, Schaap M, Zuckerman T, Volin L, Russell NH, Jindra P,

Beguin Y, Ehninger G, Ciceri F, Blaise D, Diez-Martin JL, Petersen E, Schönland S, and Garderet

L. Haplo-Identical Stem Cell Transplantation for Patients with Multiple Myeloma Who Relapsed

35

after Autografting. a Study from the Cmwp of EBMT. 59 th

ASH Annual Meeting and Exposition,

December 9-12, 2017. Atlanta, GA, USA. Blood 2017, 130, Suppl 1:2046. Poster presentation.

78. Stein J, Zuckerman T, Baar Y, Wildbaum H, Katz T, Perl-Yaffe M, Horev-Azaria L, Yarkoni S,

Nechushtan A, Rodionov G, Gez L, Rosenzwaig M, Rodin A, Pereg Y, DiPersio JF, Rowe JM, and

Yaniv I. Results of a Non-Interventional Clinical Trial of Apograft - a Novel Technology for GvHD

Prevention. 59 th

ASH Annual Meeting and Exposition, December 9-12, 2017. Atlanta, GA, USA.

Blood 2017, 130, Suppl 1:4445. Poster presentation.

79. Hardak E, Fuchs E, Rak-Cohen O, Zuckerman T. Simple spirometry monitoring is useful in

detecting late post-stem cell transplantation lung function deterioration. 44th Annual Meeting of the

European Society for Blood and Marrow Transplantation, March 18–21, 2018, Lisbon, Portugal.

Abstract # P302. Poster presentation.

80. Averbuch D, Tridello G, Hoek J, Mikulska M, Pabst T, San Segundo LY, Akan H, Ozcelik T,

Donnini I, Klyasova G, Botellho de Sousa A, Zuckerman T, Wu D, Tecchio C, de la Camara R,

Sucak G, Ljungman P, Gulbas Z, Nicolas E, Calore E, Perruccio K, Neparstek E, Annaloro C,

Matino R, Avni B, Shaw P, Gil L, Iacobelli S, Styczynski J, Engelhard D, Cesaro S. Pre-

engraftment and post-engraftment gram-negative rods bacteremia in HSCT patients: risk factors and

association with mortality. Intercontinental study of infectious diseases working party of EBMT.

44th Annual Meeting of the European Society for Blood and Marrow Transplantation, March 18–

21, 2018, Lisbon, Portugal. Abstract # O113. Oral presentation.

81. Benyamini N, Zuckerman T, Rowe JM, Katz T. High overall survival rate, in the pre-novel agent

era, following tandem autologous stem cell transplantation in newly-diagnosed patients with

multiple myeloma: Results of long-term follow-up. 44th Annual Meeting of the European Society

for Blood and Marrow Transplantation, March 18–21, 2018, Lisbon, Portugal. Abstract # P674.

Poster presentation.

82. Robin M, Chevret S, Koster L, Wolschke C, Yakoubagha I, Bourhis J-H, Chevallier P, Cornelissen

JJ, Reményi P, Maertens J, Poire X, Craddock C, Socié G, Itälä-Remes M, Schouten H, Marchand

T, Passweg J, Blaise D, Damaj G, Ozkurt ZN, Zuckerman T, Rohrlich P-S, Labussière H,

Cammenga J, Chalandon Y, Kroger N. In vivo T-cell depletion in patients with myelofibrosis

transplanted from an HLA matched sibling donor: an EBMT study. 44th Annual Meeting of the

European Society for Blood and Marrow Transplantation, March 18–21, 2018, Lisbon, Portugal.

Abstract # O047. Oral presentation.

83. Boeckh M, Dadwal S, Bergeron A, Ljungman P, Kim Y-J, Cheng G-S, Pipavath S, Limaye A,

Blanchard E, Winston D, Stiff P, Marty F, Rosenvald-Zuckerman T, LaChance S, Rahav G, Small

C, Mullane K, Patron R, Lee D-G, Hirsch H, Waghmare A, McKevitt M, Jordan R, Guo Y, German

36

P, Porter D, Gossage D, Watkins T, Chien J, Chemaly R. A Phase 2b, randomized, double-blind,

placebo-controlled trial of Presatovir (GS-5806) for treatment of hematopoietic-cell transplantation

patients with a respiratory syncytial virus upper respiratory tract infection. 44th Annual Meeting of

the European Society for Blood and Marrow Transplantation, March 18–21, 2018, Lisbon, Portugal.

Abstract # O106. Oral presentation.

84. Nevo N, Gur-Cohen S, Kollet O, Zuckerman T, Brenner B, Ben-Arush M, Lapidot T. PAR1

expression level is a positive predictive marker for efficiency of G-CSF induced human CD34+

hematopoietic stem cells mobilization and repopulation. 44th Annual Meeting of the European

Society for Blood and Marrow Transplantation, March 18–21, 2018, Lisbon, Portugal. Abstract #

P851. Poster presentation.

85. Shouval R, Labopin M, Bomze D, Baerlocher GM, Foà R, Blaise D, Haenel M, Forcade E, Huynh

A, Saccardi R, Milone G, Zuckerman T, Reményi P, Esteve J, Gorin NC, Mohty M, Nagler A.

FLT3 and NPM1 are powerful determinants of outcome in acute myeloid leukemia patients treated

with autologous stem cell transplantation: An analysis by the Acute Leukemia Working Party of the

EBMT. 60th

ASH Annual Meeting and Exposition, San-Diego, USA, December 1-4 2018. Blood

2018, 132, Suppl 1:609. Oral presentation

86. Levy-Barazany H, Pinkas L, Rodionov G, Marelly N, Tzadok M, Wildbaum H, Katz T, Bakimer R,

Yarkoni S, Peled A, Stein J Zuckerman T. Brief Ex Vivo Incubation with Fas Ligand Selectively

Depletes Alloreactive T Cells and Antigen Presenting Cells from Stem Cell Grafts. 60th

ASH

Annual Meeting and Exposition, San-Diego, USA, December 1-4 2018. Blood 2018, 132, Suppl

1:2033. Poster presentation

87. Yehudai-Reshef S, Oron B, Moskovitz Y, Gabay T, Fridman-Dror A, Sabah R, Kaushansky N,

Zuckerman T, Shlush LI. Donor Cell Leukemia: The Role of Recipient Microenvironment. 60th

ASH Annual Meeting and Exposition, San-Diego, USA, December 1-4 2018. Blood 2018,132,

Suppl 1:3853. Poster presentation

88. Lazarus HM, Metheny L, Zuckerman T, Escobar C, McGuirk JP, Rosen Y, Rowe JM. Prospective,

Multi-Center, Phase I Clinical Trial of PLX-R18 Placental Expanded Adherent Stromal Cells in

Subjects with Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation. 60th

ASH Annual Meeting and Exposition, San-Diego, USA, December 1-4 2018. Blood 2018,132,

Suppl 1:3379. Oral presentation

89. Ram R, Amit O, Zuckerman T, Gurion R, Raanani P, Bar-On Y, Avivi I, Wolach O. Addition of

Venetoclax to Patients with Acute Myeloid Leukemia Relapsing after Treatment with

Hypomethylating Agents. Multicenter Historical Prospective Study. 60th

ASH Annual Meeting and

Exposition, San-Diego, USA, December 1-4 2018. Blood 2018,132, Suppl 1:4046. Poster

presentation

37

90. Dann EJ, Sobol S, Mashiach T, Katz T, Zuckerman T. A Simple Model for Predicting Post-

Autologous Stem Cell Transplantation Outcome in Patients with Relapsed/Primary Refractory

Hodgkin Lymphoma. 60th

ASH Annual Meeting and Exposition, San-Diego, USA, December 1-4

2018. Blood 2018,132, Suppl 1:2150. Poster presentation

91. Henig I, Yehudai-Ofir D, Leiba R, Lavi N, Ringelstein-Harlev S, Zuckerman T. Autologous stem

cell transplantation with reduced-dose BEAM/BEAC is feasible for patients ≥70 years old and

yields similar results as full-dose conditioning in patients aged 65-69. 45th Annual Meeting of the

European Society for Blood and Marrow Transplantation. Frankfurt, Germany, 24th–27th March,

2019. Poster presentation

92. Ofran Y, Leiba R, Rosenberg D, Henig I, Yehudai-Ofir D, Haddad N, Fineman R, Frisch A,

Okasha D, Carasso Y, Zuckerman T, Horesh N. NPM1 Quantitative Monitoring of Minimal

Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for

Allogeneic Stem Cell Transplantation without Affecting Their Survival. 61st ASH Annual Meeting

and Exposition, December 7-10, 2019. Orlando, Florida, USA. Blood 2019, 134, Suppl 1: 2603.

Poster presentation

93. Yehudai-Reshef S, Sabah R, Gabay T, Zuckerman T. Changes in the Main Bone Marrow Cell

Subpopulations May Potentially Contribute to the Initiation of Acute Myeloid Leukemia. 61st ASH

Annual Meeting and Exposition, December 7-10, 2019. Orlando, Florida, USA. Blood 2019, 134,

Suppl 1: 2494. Poster presentation

94. Altman JK, Zuckerman T, Frankfurt O, Luger SM, Bixby DL, Kota V, Burch MM, Wolach O,

Levi I, Gourevitch A, Ram R, Flaishon L, Tessler S, Gengrinovitch S, Ben Yakar R, Rowe JM.

Aspacytarabine (BST-236) Is Safe and Efficacious as a Single-Agent, First-Line Therapy for

Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a

Phase 1/2a and an Ongoing Phase 2b. 61st ASH Annual Meeting and Exposition, December 7-10,

2019. Orlando, Florida, USA. Blood 2019, 134, Suppl 1: 179. Oral presentation

95. Amit O, Bar-On Y, Avivi I, Zuckerman T, Perets G, Henig I, Levi I, Yehudai-Ofir D, Ringelstein

Harlev S, Ram R. Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and

Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic

Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study. 61st ASH Annual

Meeting and Exposition, December 7-10, 2019. Orlando, Florida, USA. Blood 2019, 134, Suppl

1:5654. Poster presentation

38

National

1. Zuckerman T, Sahar D, Streichman S, Hertz E, Mandel R, Atias D, Eldar I, Rowe JM, Zuckerman

E. BCL2 and immunoglobin gene rearrangement in patients with HCV infection. Winter Meeting of

the Israel Society of Hematology and Blood Transfusion, Herzliya, February 1999 (oral

presentation).

2. Rosenbaum H, Gavish I, Avivi I, Haddad N, Hoffman R, Arbov L, Nadir Y, Zuckerman T,

Brenner B, Dann E, Carter A, Rowe JM. Autologous peripheral blood stem cell transplantation

(PBSCT) in multiple myeloma. Results in 38 patients. Annual Meeting of the Israeli Society of

Hematology and Blood Transfusion, Herzliya, February 8, 2000 (oral presentation).

3. Dann EJ, Haddad N, Hoffman R, Fineman R, Arbov L, Rosenbaum H, Zuckerman T, Ben-Shachar

V, Haim N, Epelbaum R, Rowe JM. High-dose cyclophosphamide in CHOP regimen is safe and

efficacious for aggressive non-Hodgkin lymphoma, and does not impair fertility of female patients.

Annual Meeting of the Israel Society of Hematology and Blood Transfusion, Tel Aviv, July 2, 2002

(oral presentation).

4. Dann EJ, Badian E, Avivi I, Haddad N, Stravets T, Fineman R, Elhasid R, Bonstein L, Oliven A,

Kertsman A, Zuckerman T, Rowe JM. Extracorporeal photochemotherapy for acute and chronic

GvHD: report of 43 patients treated in a single institution. Annual Meeting of the Israel Society of

Hematology and Blood Transfusion, Tel Aviv, January 2003 (oral presentation).

5. Dann E, Bar-Shalom R, Haim N, Tamir A, Ben-Shachar M, Avivi I, Zuckerman T, Kirschbaum

M, Goor O, Libster D,

Rowe JM, Epelbaum R. BEACOPP regimen based on early scintigraphy can

reduce the cumulative doses of chemotherapy for standard and high risk Hodgkin lymphoma (HD)

with no impairment of outcome. Annual Meeting of the Israel Society of Hematology and Blood

Transfusion, Tel Aviv, November 2005 (oral presentation).

6. Zuckerman T, Katz T, Haddad N, Fineman R, Avivi I, Dann EJ, Sahar D, Oliven A, Hertz E,

Ofran Y Akria L, Markovitz M, Faibish T, Rowe JM. Allogeneic stem cell transplantation (ASCT)

in CML with partial T-cell depletion − no prophylaxis for graft-versus-host disease (GvHD) and

preemptive DLI for patients with post-transplant minimal residual disease (MRD): An alternative

approach in CML transplantation with low morbidity and long term disease free survival. Annual

Meeting of the Israel Society of Hematology and Blood Transfusion, Nahariya, November 2006

(oral presentation).

7. Zuckerman T. Current indications for allogeneic SCT in acute leukemia. Preceptorship in Acute

Leukemia. Meeting under the auspices of the Israel Society of Hematology and Blood Transfusion.

Haifa, Israel, April 1-2, 2019 (invited speaker).

39

15.3 Participation in Organizing Conferences

1. 6th

International Symposium: Haploidentical Stem Cell Transplantation Jerusalem, Israel,

September 2010. Invited chairperson

2. XXXIII World Congress of the International Society of Hematology, Jerusalem, Israel, October

2010. Invited chairperson.

3. Annual Meeting of the Israel Society of Hematology and Blood Transfusion, Dead Sea, October

– November 2014. Chairperson.

4. 1st Greco-Israeli Hematology meeting, April 2018, Thessaloniki, Greece. Israeli Coordinator of

the Bone Marrow Transplantation Working Group,

16. SIGNIFICANT PROFESSIONAL PROJECTS/ACTIVITIES

2016 International project for the establishment of a Stem Cell Transplantation Unit in Tbilisi,

Georgia

40

RESEARCH ACCOMPLISHMENTS

I have been serving as the Head of the Stem Cell Transplantation Unit (Rambam Health Care

Campus) since 2006. To date, more than 2300 stem cell transplants (approximately 150

transplantations per year) have been performed. During this period, I developed the Intensive Care

Unit for hematological patients. My main interests have been focusing on both clinical and basic

research related to hematological malignancies and stem cell transplantation. Initiation of multiple

clinical studies performed at the Unit became possible owing to the establishment of a large detailed

database specifically developed for these purposes.

1. Leukemia Research

Two years ago, I established the Leukemia Research Laboratory (Clinical Research Institute at

Rambam) focusing on the investigation of the heterogeneity of acute leukemia employing the

unique approach of single leukemic cell analysis and the contribution of the microenvironment to

leukemic initiation and propagation.

Acute leukemia in adults is characterized by complete response to initial therapy in the majority of

patients; however, most often this is followed by relapse. It has been recently appreciated that acute

leukemia is a genetically heterogenic disease with significant inter-patient variability. We have

demonstrated that there is also significant intra-patient variability. Using single-cell analysis, we

were able to show that with segregation of the tumor into single cells, we can identify

subpopulations with a specific genetic profile that was not detected by conventional bulk DNA

analysis. These findings have implications not only on choosing the right combinational therapy,

but also on understanding the order of acquisition of mutations [Ref 10, Basic Research].

Additionally, adopting strategies from the investigation of population analysis, we were able to

demonstrate significant heterogeneity in the replication rate between different leukemias, where in

some the origin comes from a rarely dividing leukemic stem cell, while in others microsatellite

instability is operating [Ref 9, Basic Research]. We have currently received a grant dedicated to the

in-depth genetic analysis of 23 common AML mutations in each single cell. This will be coupled

with construction of a phylogenetic tree of each cell at diagnosis and relapse. Additionally, the

results of our study designed to evaluate the association of leukemic cells with bone marrow stroma

(i.e., the microenvironment) have been recently published [Ref. 11, Basic Research]. To conduct the

above studies, the generation of leukemic clones from single cells is needed. In collaboration with

Prof. Uri Sivan from the Faculty of Physics at the Technion, we have generated a nano-device

41

capable of entrapping single cells and growing them to colonies. This device is developed with the

aid of the Magneton grant.

2. Clinical Research on Infectious Complications in Stem Cell Transplantation/Lymphoma

The association of chronic infections (viral, bacterial) and the development of lymphoma was

reported in the early 1990s. We were among the first groups describing the association between

lymphoma and chronic hepatitis C infection and its implication on lymphoma treatment [Refs 2-5;

Ref 7, Clinical Research]. Additionally, in recent years we have focused on the occurrence of

resistant bacteria in transplant patients and an innovative approach to its eradication [Refs 29-32,

Clinical Research]. We have also investigated the radiographic appearance [Ref 11, Clinical

Research] and early detection [Ref 32, Clinical Research] and treatment [Ref 7, Clinical Research]

of lung Aspergillosis in transplanted patients as well as management of viral infections in this

patient population [Refs 28, 29, Clinical Research].

3. Clinical Research in Stem Cell Transplantation and Leukemia

The successful outcome of stem cell transplantation depends on many variables, including risk-

adapted approach to patient selection, type of transplant, appropriate conditioning, post-transplant

immune intervention, and early detection and treatment of transplant-related complications.

An innovative approach to stem cell transplantation in chronic leukemia with immune intervention

tailored based on individual risk stratification was developed at the Rambam SCT Unit [Ref 16,

Clinical Research]. The role of autologous stem cell transplantation in favorable leukemia was

studied and the findings were presented at the international conference [Abst 57]. Safety of SCT for

elderly patients was recently demonstrated [Abst 51]. Studies assessing fertility issues in SCT [Ref

13 & Ref 17, Clinical Research], novel mode of therapy for pulmonary hemorrhage developing post

SCT [Ref 12, Clinical Research], and pharmacokinetics of agents administered during

transplantation and influence of the genetic polymorphism on drug metabolism [Ref 21 & Ref 24,

Clinical Research] and their association with SCT complications [Ref 18, Clinical Research] have

been conducted. GVHD is a major obstacle to successful stem cell transplantation and is associated

with significant morbidity and mortality. Pre-transplant prediction of GVHD may allow early

intervention. Recently, we were able to show that semaphorin 3A expression on patient and donor

regulatory cells could predict its occurrence. This project is planned to continue on a larger scale

with in-depth search for possible mechanisms of involvement of regulatory T cells in protection

against GVHD with potential implications for early intervention. Additionally, several phase I/II

studies are underway looking at pre-apoptotic signaling to prevent GVHD [Ref 23, Clinical

42

Research & Abst. 52]. Treatment of GVHD is a composite challenge. The use of mesenchymal cells

[Ref 20] as possible GVHD treatment has been assessed, and we are now launching a new study in

collaboration with Prof. Karin (Immunology Department, Rappaport Faculty of Medicine,

Technion) examining the role of CCL-1 chemokine and CCL1-Ig as a possible drug for the

treatment of GVHD. I have been an initiator and principal investigator of a phase I study using Fas-

L exposure of stem cell harvest aiming to ameliorate acute GVHD [Absts 56, 60, 70, 85]. In an

attempt to overcome poor graft function, I serve as the Israeli principal investigator of the

international phase I study employing post-transplant application of mesenchymal stem cells for this

purpose.

In the area of acute leukemia, I am one of the initiators and principal investigator of preclinical

studies of the novel therapeutic agent BST-236 for AML, which has led to completion of phase I/IIa

study and launching an international phase II study. Data were presented as an oral presentation at

the 59th

annual meeting of the American Society of Hematology [Abst 74].

Due to my extensive experience in the fields of acute leukemia and stem cell transplantation, I was

invited to write book chapters and reviews that were published over the years in peer-reviewed

journals [Ref 1-11]. In the prestigious ongoing series of "How I Treat …" in the Blood Journal, I

have addressed the issue of treatment for hematologic emergencies in adults with acute leukemia

[Ref 3].

43

Contribution in the List of Publications

Basic Research

Clinical Research

Publication No. Contribution

1 BD

2 BD

3 ABCD

4 ABCD

5 ABCD

6 ABCD

7 ABCD

8 BCD

9 ABCD

10 ABCD

Publication No. Contribution

1 BCD

2 ABCD

3 ABCD

4 BCD

5 BCD

6 ABCD

7 BCD

8 BCD

9 ABCD

10 ABCD

11 BCD

12 BCD

13 ABCD

14 ABCD

15 ABCD

16 ABCD

44

Reviews

17 ABCD

18 ABCD

19 ABCD

20 BD

21 BCD

22 ABCD

23 ABCD

24 BCD

25 ABCD

26 ABCD

27 BC

28 BCD

29 BCD

30 BCD

31 B

32 ABC

33 B

34 BCD

35 BCD

36

Contribution Publication No.

B,C,D 1

B,C,D 2

B,C,D 3

B,C,D 4

B,C,D 5

B,C,D 6

B,C,D 7

B,C,D 8

B,C,D 9

10

45

Case Reports

Publication No. Contribution

1 BC

2 ABCD

3 BC

4 AC

5